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ABSTRACT
Enterobactin (Ent)-mediated high affinity iron acquisition is critical for Gram-negative bacteria
to survive in the host. Given the bacteriostatic effect of lipocalin resulting from its potent Entbinding ability, immune intervention directly targeting Ent is promising for iron-dependent
pathogen control. Moreover, passive immunization with Ent-specific egg yolk antibody (IgY) is
a promising alternative to antibiotics to prevent and treat bacterial infections. In the first study,
using a simple method, we successfully conjugated purified Ent to different carriers including
keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), and CmeC, a vaccine
candidate for Campylobacter control. Subcutaneous immunization of rabbits with the KLH-Ent
conjugate triggered strong systemic IgG immune response with up to 16,384 fold increase in IgG
titer directed against whole conjugate and up to 4,096 fold increase in the level of specific antiEnt IgG. The Ent-specific IgG also displayed exceptional reactivity to ferric Ent, linear trimer of
Ent, and different salmochelins. Growth assays further demonstrated the Ent-specific antibodies
significantly inhibited Ent-dependent growth of Campylobacter spp. and E. coli. In the second
study, using different vaccination regimens, we immunized laying hens with different Ent
conjugate vaccines to produce Ent-specific egg yolk IgY. In the first trial, Barred Rock layers
(n=3) were intramuscularly immunized with the KLH-Ent conjugate vaccine, which triggered
significant immune response in layers, leading to moderately increased titers of Ent-specific IgY
in serum (up to 8 folds) and yolk (up to 2 folds). In the second trial, Rhode Island Red layers
were subcutaneously immunized with specific Ent conjugates (KLH-Ent, BSA-Ent, or CmeCEnt; n=2 per conjugate). ELISA analysis indicated that anti-Ent IgY titers dramatically increased
in serum (up to 2,048 fold) and yolk (up to 1,024 fold) of each individual layer upon vaccination
with KLH-Ent or CmeC-Ent. However, the BSA-Ent conjugate failed to induce anti-Ent IgY.
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The hyperimmune egg yolks were pooled and lyophilized for future evaluation of in vivo passive
immune protection. Collectively, these studies have provided solid foundation for developing
innovative and effective Ent-dependent immune interventions again Gram-negative bacterial
infections in the future.

Key words: enterobactin, iron acquisition, conjugate vaccine, egg yolk IgY, Gram-negative
pathogens
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CHAPTER I: Review of Literature
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1.1 Siderophore-mediated iron acquisition in bacteria
Iron is a vital nutrient for nearly all prokaryotic and eukaryotic cells. Its role ranges from
energy generation and DNA replication to oxygen transport and protection against oxidative
stress (Skaar, 2010). Because of the insolubility of ferric hydroxide, the concentration of Fe(III)
in water is very low (10-18 M). Mammalian iron-binding proteins further reduce the concentration
of free Fe(III) to an estimated 10-24 M in human serum (Raymond et al., 2003). This scarcity of
free iron presents a challenge for bacterial cells, which require a cytoplasmic iron concentration
of ~10-6 M for growth (Andrews et al., 2003). Bacteria have responded to this selective pressure
by evolving the ability to acquire iron via numerous (and often redundant) mechanisms,
primarily including the high-affinity iron acquisition mediated by utilization of small chelators
with high affinity for Fe(III), known as siderophores, and the direct use of host iron-binding
proteins (e.g., transferrin, lactoferrin, hemoglobin, and hemopexin) without utilization of
siderophores (Fischbach et al., 2006; Skaar, 2010).
1.1.1 Direct use of host iron-binding proteins
As most iron in humans is contained within hemoglobin, many bacterial pathogens have
developed mechanisms to liberate hemoglobin from erythrocytes and utilize heme as iron source.
The requirement for heme may be satisfied through endogenous heme production, exogenous
heme acquisition, or combination of both (Cassat & Skaar, 2013). There are two major classes of
bacterial heme acquisition systems: hemophore-dependent system and direct heme uptake system
(Anzaldi & Skaar, 2010). For hemophore-dependent system, bacterial pathogens can utilize
hemophores to scavenge heme from host hemoproteins and deliver heme to bacterial cells
through hemophore receptors. They are functionally analogous to siderophores but specifically
target heme, while siderophores target iron atoms (Wandersman & Delepelaire, 2004). For direct
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heme uptake system, it typically involves surface receptors that recognize either heme or hemebinding hemoproteins, such as hemoglobulin or hemopexin. Subsequently, Heme is removed
from hemoproteins and transported through envelop of bacteria into the cytoplasm. Once inside
the cytoplasm, the iron is released from heme through the action of heme oxygenase or reverse
ferrochelatase activity (Létoffé et al., 2009; Reniere et al., 2007; Wilks, 2002).
Mammals can also employ transferrin and lactoferrin to reduce the level of free
extracellular iron. However, some bacteria are capable of direct recognition of transferrin and
lactoferrin via surface-exposed receptors. Transferrin and lactoferrin receptors have been
identified in various pathogenic bacteria, such as Neisseria species (Cornelissen & Sparling,
1994). These receptors are located in the outer membrane and induced by iron starvation. Iron is
stripped from transferrin and lactoferrin at the bacterial cell surface and the iron-free proteins are
released extracellularly rather than internalized and accumulated within bacterial cell (Andrews
et al., 2003).
1.1.2 Production and utilization of siderophores for iron acquisition
Siderophores are of low molecular mass (<1,000 Da) and characterized by their high
specificity and affinity towards Fe(III). When inside a host, these compounds capture iron from
proteins such as hemoglobin, transferrin, or lactoferrin. Subsequently, iron-loaded siderophores
are transported into the bacterial cell, where iron is released either by hydrolysis of the
siderophores or by reduction of Fe(III) to Fe(II) (Faraldo-Gómez & Sansom, 2003). Siderophores
are divided into three main classes based on the chemical nature of the moieties donating the
oxygen ligands for Fe(III) coordination: catecholates, hydroxamates, and carboxylates. In
addition, a panel of siderophores can have different classes of moieties within single molecule,
resulting in “mixed-type” siderophores (Miethke & Marahiel, 2007).
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The biosynthesis of siderophores in bacterial pathogens is induced by intracellular iron
deficiency. There are two pathways involved in the synthesis of siderophores: one is dependent
on nonribosomal peptide synthatases (NRPS) and the other is independent of NRPS (Saha et al.,
2013). NRPS represents large multi-enzyme complexes that activate and assemble a broad array
of amino, carboxy, and hydroxyl acids, leading to macrocyclic peptidic products with high
structural variability (Grünewald & Marahiel, 2006). NRPS is mainly responsible for the
synthesis of aryl-capped siderophores, such as pyochelin and pyoverdine in Pseudomonas
aeruginosa, enterobactin in Escherichia coli, Salmonella enterica, and Klebsiella
spp., and mycobactin in Mycobacterium tuberculosis. The NRPS-independent pathways are used
for production of hydroxamate and carboxylate siderophores, such as petrobactin in Bacillus
anthracis, alcaligin in Bordetella pertussis, and staphyloferrin A and B in Staphylococus aureus
(Saha et al., 2013).
In Gram-negative and low GC-content Gram-positive bacteria (e.g. Bacillus spp.), Fur
(ferric uptake regulator) plays a critical role in regulation of siderophore production and iron
homeostasis, whereas in high GC-content Gram-positive bacteria, such as Streptomyces and
Mycobacteria, diphtheria toxin regulator (DtxR) controls siderophore-mediated iron acquisition
(Saha et al., 2013). Fur protein (~17 kDa) acts as a repressor, using ferrous ion as a cofactor by
binding to the consensus operator site, designated “iron box”, of iron acquisition genes (Skaar,
2010). With respect to DtxR, it displays very low or no sequence similarity to Fur but functions
similarly to Fur by negatively regulating genes involved in iron acquisition and virulence factor
(Andrews et al., 2003). In addition to these common repressors, there are several transcriptional
regulators that control siderophore biosynthesis and utilization and act as activators by sensing

4

the iron-siderophore complex, either intracellularly or extracellularly (Miethke & Marahiel,
2007).
The export of siderophores out of bacterial cell is carried out by efflux pumps.
Siderophore secretion requires the activity of at least one of the following efflux pump families:
major facilitator superfamily (MFS), ATP-binding cassette (ABC), and resistance/nodulation/cell
division (RND) that is specific for Gram-negative organisms (Wilson et al., 2016). The
enterobactin secretion pathway has been well characterized in E. coli, which involves stepwise
process using complex machinery systems. Briefly, enterobactin is transported from the
cytoplasm to the periplasm via EntS (MFS-class efflux pump), followed by crossing outer
membrane through the concerted action with aid of inner membrane RND-type efflux pump
(AcrB, AcrD, or MdtABC) and the outer membrane protein channel TolC (Horiyama & Nishino,
2014).
Once Fe(III) is mobilized and captured by the secreted siderophore, the Fe(III)siderophore complex is accessible for assimilation by bacteria (Miethke & Marahiel, 2007). In
Gram-negative bacteria, the Fe(III)-siderophore complex is recognized by a specific outer
membrane receptor (OMR) and subsequently transported through the receptor channel using
TonB-ExbB-ExbD energy transduction system, in which TonB is an inner membrane-anchored,
periplasm-spanning protein, while ExbB and ExbD proteins are embedded in inner membrane.
The TonB-ExbB-ExbD system transduces the proton motive force energy to the OMR to allow
translocation of Fe(III)-siderophore into cytoplasm via an inner membrane ABC transporter
system (Schalk & Guillon, 2013). In contrast, Gram-positive bacteria have only a single
membrane and therefore possess a simpler siderophore uptake system. In general, Gram-positive
bacteria express siderophore-binding protein (SBP), associated with a permease. SPB binding to
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an extracellular iron-siderophore causes a conformational change in the SBP-permease complex,
allowing transport of the iron-siderophore across the membrane into the cytoplasm (Wilson et
al., 2016).
After the transport of Fe(III)-siderophore complex into bacterial cell, release of iron
involves hydrolysis or modification of the siderophore scaffold and/or reduction of the
coordinated Fe(III). It can occur either in cytoplasm or in periplasm, depending on specific
siderohpore pathway and organism (Schalk & Guillon, 2013). The reduction of Fe(III) to Fe(II)
by reductases would greatly reduce its affinity to siderophore, consequently leading to release of
iron. Most reductases have no significant specificity for their iron-siderophore substrates,
suggesting that reductive iron release has not led to the development of highly specialized
enzymes but led to the involvement of already established reductase activity (Miethke &
Marahiel, 2007). In contrast, specialized enzymes are employed by iron-siderophore hydrolysis,
leading to a dramatic loss of complex stability and hence facilitating the subsequent removal of
the iron. This is a fairly limited strategy since it is feasible only if the siderophore structure
provides a hydrolysable backbone that allows enzymatic degradation. It is also more costintensive to the bacteria than ferrisiderophore reduction because hydrolytic iron release results in
destruction of siderophore scaffold (Miethke & Marahiel, 2007).

1.2 Enterobactin-mediated iron acquisition in Gram-negative bacteria
1.2.1 General features
Enterobactin, a catecholate siderophore that has the highest affinity for Fe(III) of all
natural siderophore compounds, is an archetype for iron acquisition in Gram-negative bacteria
(Raymond et al., 2003). Many species of Gram-negative enteric bacteria such as E. coli, S.
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enterica, Shigella dysenteriae, and K. pneumoniae harbor a ~24-kb gene cluster encoding 13
proteins that collaborate to synthesize, transport, and process enterobactin. Enterobactin is a 2,3dihydroxybenzoylserine (DHB-Ser) trilactone and assembled from 2,3-dihydroxybenzoic acid
(DHBA) and serine by NRPS that comprises EntE, EntB, and EntF. The primary metabolite
chorismate is diverted to DHB by successive action of EntC, EntB, and EntA, whereas EntD
catalyzes the post-translational 4’-phosphopantetheinylation of EntB and EntF that is required
for covalent tethering of assembly-line intermediates. Following synthesis in the cytoplasm,
enterobactin is exported through the inner membrane by EntS, a major facilitator superfamily
exporter, and through the outer membrane by a TolC-dependent mechanism (Fischbach et al.,
2006).
Once secreted outside of bacterial cell, enterobactin can successfully compete for Fe(III)
binding with all known protein and small-molecule ligands, given its remarkably strong affinity
to Fe(III). The ferric enterobactin (FeEnt) complex is then imported through the outer-membrane
enterobactin-specific OMR, such as FepA in E. coli, in a TonB-dependent process, escorted
through the periplasm by FepB, and pumped through the two-protein inner-membrane channel
FepDG into the cytoplasm by FepC-catalyzed ATP hydrolysis (Fischbach et al., 2006).
Liberation of Fe(III) from FeEnt complex requires enzymatic degradation of its trilactone
scaffold to three equivalents of DHB-Ser by the esterase Fes (Lin et al., 2005). The entire
enterobactin system is under transcriptional control by the iron-dependent repressor Fur, which
serves as a sensor for intracellular iron concentration. Thus, transcription of the enterobactin
synthesis, export, and import genes is activated during low-iron conditions and repressed when
iron is abundant (Fischbach et al., 2006).
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1.2.2 FeEnt receptors
FeEnt receptors, as the outer membrane “gatekeepers”, can bind the FeEnt with high
affinity for internalization in Gram-negative bacteria. Generally, the receptors are induced by
iron starvation and are not present under iron-sufficient conditions. One important reason for this
may be the targeting of OMRs by bacteriophages, microcins, and antibiotics as an entry point
into bacterial cells (Andrews et al., 2003). There are often multiple FeEnt receptors within the
same Gram-negative species, each possessing varied affinity to enterobactin and its derived
products. For example, in E. coli, there are up to five FeEnt receptors (FepA, Cir, Fiu, IroN, and
Iha) binding to enterobactin and its derivatives (Wang et al., 2019); in Campylobacter, CfrA and
CfrB have been identified to bind FeEnt complex (Zeng & Lin, 2014). Such redundancy
indubitably provides bacteria survival advantages via versatile FeEnt uptake. However, since
such surface-exposed iron-regulated outer membrane proteins have been intensively targeted as
vaccine candidates, the redundant FeEnt receptors within the same Gram-negative species may
raise significant challenges for developing enterobactin receptors associated pathogen control
(Wang et al., 2019).
The transport of FeEnt through OMRs also requires energy, which is provided by
electrochemical charge gradient of the cytoplasm and is delivered by the energy-transducing
TonB-ExbB-ExbD protein complex. ExbB and ExbD are integral cytoplasmic proteins whereas
TonB is periplasmic and anchored to the cytoplasm by its hydrophobic N-terminal domain. It is
believed that ExbB and ExbD use the membrane electro-chemical charge gradient to produce an
“energized” form of TonB that subsequently mediates a conformational change in the liganded
OMR. This in turn leads to translocation of the associated FeEnt to the periplasm and
deenergisation of TonB (Andrews et al., 2003). There are diverse types of TonB-ExbB-ExbD
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systems energizing FeEnt uptake in different Gram-negative bacteria. For instance,
Campylobacter possesses up to three TonB systems while E. coli has only one. The presence of
multiple TonB systems within a single organism implies that these TonB systems may be able to
compensate each other for iron acquisition (Naikare et al., 2013).
1.2.3 Enterobactin-dependent iron acquisition in Campylobacter
Campylobacter species, primarily including C. jejuni and C. coli, are the most common
causative bacterial pathogen of human gastroenteritis in the United Sates and other industrialized
countries. It establishes persistent and benign infection in chicken’s gut (up to 1010 CFU per
gram of feces) while causes significant inflammation and enteritis in humans (Zeng & Lin,
2014). To establish in vivo colonization, Campylobacter has evolved effective mechanisms,
including siderophore-mediated iron acquisition, to counteract the iron-restricted intestinal
conditions. Notably, Campylobacter does not inherently produce any siderophore, but it can
utilize siderophores produced by other microorganisms. To date, enterobactin is the only known
physiologically relevant siderophore utilized by Campylobacter for in vivo colonization,
suggesting Campylobacter as an ideal model organism to examine key issues of enterobactinmediated iron scavenging by Gram-negative bacteria (Zeng & Lin, 2014).
Two FeEnt receptors (CfrA and CfrB) on the outer membrane have been demonstrated to
be induced under iron-restricted conditions and transport FeEnt from extracellular environment
into periplasm. CfrA is prevalent in Campylobacter strains from diverse sources while CfrB is
produced in the majority of C. coli and a small population of C. jejuni. Chicken studies indicate
that both CfrA and CfrB play critical roles in in vivo colonization of Campylobacter, suggesting
both as promising subunit vaccine candidates against Campylobacter (Xu et al., 2010; Zeng et
al., 2009). Unlike many Gram-negative bacteria that have one type of TonB-ExbB-ExbD energy
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transduction system to energize the transmembrane transport of FeEnt, Campylobacter possesses
up to three TonB-ExbB-ExbD systems, whose redundancy may allow Campylobacter to utilize
different iron sources (Zeng & Lin, 2014; Zeng et al., 2013b).
Upon arriving in the periplasm, FeEnt is hydrolyzed by the esterase Cee, which appears
to be the sole enterobactin esterase in Campylobacter. Cee, located in the periplasm, is
demonstrated to be not only essential for CfrB-dependent FeEnt acquisition but also able to
utilize CfrA-transported FeEnt when the CeuBCDE ABC transporter on the inner membrane is
not functional (Zeng et al., 2013a). The degraded products of FeEnt by Cee may follow two
routes: one is the immediate release/transfer of Fe(III) from the low-affinity DHBS monomers
and/or dimers; the other is the transport of linear Fe(III)-(DHBS)3 into cytoplasm. In CfrAdependent pathway, FeEnt is likely to be subject to uncharacterized reductive iron release
mechanisms in the cytoplasm, which may confer an advantage of reutilizing intact enterobactin
(Zeng & Lin, 2014).

1.3 Evolution of Ent-mediated iron acquisition: “tug of war” between host and bacterial
pathogens
1.3.1 Enterobactin-binding protein lipocalin 2
The battle for iron between host and bacterial pathogens can be regarded as a scenario of
coevolution (Miethke & Marahiel, 2007). The pathogen responds to iron scarcity within the host
by developing siderophore-dependent high-affinity iron acquisition. Enterobactin has unmatched
affinity for iron, however, its ability to acquire iron in the microenvironments of a mammalian
host has been called into question (Fischbach et al., 2006). The quantity of FeEnt available for
bacterial cell import is reduced by the hydrophobicity of its three catecholic acyl “arms”, which
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cause Ent to partition into lipid bilayers (Luo et al., 2006). Also, mammalian protein serum
albumin, present in serum microenvironments, has a reasonably high affinity for Ent (Konopka
& Neilands, 1984), which also compromises the efficacy of Ent-mediated iron acquisition.
More importantly, Ent-mediated iron acquisition is efficiently impaired by the 24-kDa
ligand-binding protein siderocalin (also named lipocalin 2 [Lcn2], neutrophil gelatinaseassociated lipocalin [NGAL], or 24p3), which is a member of the lipocalin superfamily and is
secreted as an acute-phase protein by neutrophils and epithelial cells during inflammation and
rapid cell growth in mammals (Flo et al., 2004; Goetz et al., 2002). Lipocalin 2 is shown to have
potent binding affinity for FeEnt complex and lower affinity for Fe(DHB)3 complex. Thus,
lipocalin 2 is able to successfully compete with the high-affinity FeEnt uptake system of enteric
bacteria (Miethke & Marahiel, 2007). In addition, the crystal structure of the lipocalin 2:FeEnt
ternary adduct also shows large sections of the lipocalin 2 calyx remain unfilled by FeEnt,
therefore lipocalin 2 may be capable of binding larger catecholate siderophores (Raymond et al.,
2003). It is also supposed that the employment of innate defense proteins for siderophore
neutralization is likely due to the fact that siderophores are hardly recognized as antigens by the
adaptive immune response if not presented in surface-immobilized forms (Miethke & Marahiel,
2007). Last but not least, L-norepinephrine (NE), a host neuroendocrine catecholamine, can
support bacterial iron acquisition by mobilizing iron from a primary source such as holo
transferrin to increase its bioavailability for bacterial uptake. However, it is shown that lipocalin
2 can also bind iron-complexed NE with high affinity and therefore inhibit the NE-mediated
growth of E. coli strains that are either capable or incapable of producing the endogenous
enterobactin. This indicates that NE directly serves as an iron source for bacterial uptake and
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lipocalin 2 functions as an antagonist for this iron acquisition process complementary to
enterobactin-mediated one (Miethke & Skerra, 2010).
1.3.2 Salmochelins, glycosylated enterobactin derivatives, evade the binding of lipocalin 2
Rather than accepting a heavy loss to host defenses, enterobactin-producing Gramnegative bacteria, such as E. coli, Salmonella, Shigella, and Klebsiella, use enzymes encoded by
a mobile cluster of genes to modify enterobactin so that the resulted iron-scavenging molecules,
named salmochelins, can circumvent unfavorable partitioning and sequestration of lipocalin 2
and serum albumin (Fischbach et al., 2006). The five-gene iroA encodes two enzymes (IroB and
IrE) that modify Ent into salmochelins before their secretion, two enzymes (IroC and IroN) that
export salmochelins and import the iron-salmochelin complex, and one enzyme (IroD) that
degrades the complex to release iron. This gene cluster was first discovered in Salmonella and is
regulated by the iron-dependent repressor Fur (Fischbach et al., 2006).
IroB is a member of the glycosyltransferase family and catalyzes the C-glycosylation of
enterobactin, adding a bulky glucose (Glc) to one or more of the catecholic “arms” of
enterobactin. IroB is demonstrated to be necessary and sufficient for salmochelin production,
suggesting a central role of this enzyme in the conversion of enterobactin to salmochelins (Bister
et al., 2004). Purified IroB acts distributively to transfer one, two, or three Glc to C5 of the DHB
moiety of enterobactin, creating mono- (MGE), di- (DGE), and triglucosyl-enterobactin (TGE)
(Fischbach et al., 2005). The modification likely prevents enterobactin from being sequestered
by lipocalin 2 but does not affect the ability of enterobactin to bind iron (Luo et al., 2006), as the
binding pocket of lipocalin 2 does not appear to be large enough to accommodate a glucose
appended to enterobactin (Fischbach et al., 2006).
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IroE catalyzes single-time hydrolysis of enterobactin and DGE in the periplasm, yielding
their respective ring-opened linear trimers before export. This modification increases the
hydrophilicity of enterobactin and DGE, while decreasing their affinity for iron only modestly.
Enterobactin has a high partition coefficient, so when enterobactin partitions into a lipid bilayer,
its iron-binding rate decreases because it is sequestered from iron that resides in the aqueous
phase. In contrast, DGE has a 5-fold lower partition coefficient, and linearized DGE has a 30fold lower partition coefficient (Luo et al., 2006). As a result, both DEG and linearized DGE
show higher rates of iron acquisition in the presence of phospholipid vesicles. Therefore, IroEcatalyzed hydrolysis of DGE prior to export will make linearized DGE a more efficient iron
scavenger in membrane-rich microenvironments, such as those commonly found in animals
(Fischbach et al., 2006). After the ferric complexes of enterobactin, DGE, and linearized DGE
have been imported to the bacterial cytoplasm, IroD exhaustively hydrolyzes them to DHB-Ser
and Glc-DHB-Ser monomers, which facilitates iron releases. It is worth noting that in
enterobactin system, Fes can only efficiently hydrolyze enterobactin to release iron, but it is not
able to hydrolyzes DGE, indicating its inability to liberate iron from DGE (Lin et al., 2005; Zhu
et al., 2005).
IroN shows 52% amino acid sequence identity to FepA, the TonB-dependent outermembrane receptor for enterobactin. It has been shown to mediate the import of FeEnt complex
and salmochelins through the outer membrane (Bäumler et al., 1998; Hantke et al., 2003). In
contrast, FepA and other catecholate-specific OMRs transport Fe(III)-bound Ent but not
salmochelins, suggesting that IroN is necessary to import salmochelins arising from the action of
IroB (Hantke et al., 2003). In addition, IroC has considerable similarity to eukaryotic ATPdriven MDR (multiple drug resistance) exporters (Müller et al., 2009). It is shown in S. enterica,
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IroC exports both Ent and salmochelins, but it is not required for utilization of FeEnt or Fesalmochelin complexes, while the ABC transporter protein FepD is required for utilization of
both siderophores (Crouch et al., 2008).

1.4 Siderophore-mediated iron-dependent bacterial pathogen control
Siderophore-mediated iron acquisition is an important virulence factor in many bacterial
pathogens. This process involves complex siderophore biosynthetic mechanisms, dedicated ferric
siderophore export and import machineries, and various enzymes to release siderophore-bound
iron following cellular uptake. Thus, the potential of utilizing siderophores or targeting
siderophore biosynthetic and transport machineries for bacterial pathogen control has been
attracting significant research interest (Zheng & Nolan, 2014). In general, three classes of
strategies have been investigated to combat bacterial infection: 1) To use the “Trojan horse”
concept by employing siderophore as a mediator to facilitate the cellular uptake of antibiotic
compounds; 2) To create artificial iron starvation for pathogens by applying iron-competing
metal ions or competitive siderophores that cannot be utilized by the pathogen; 3) To impair the
availability of siderophore for pathogens by inhibiting corresponding siderophore synthesis; 4)
To develop vaccine by targeting gatekeeper OMR to inhibit iron uptake (Miethke & Marahiel,
2007; Wilson et al., 2016).
1.4.1 Siderophore as “Trojan horse” for antimicrobial delivery
The “Trojan horse” strategy is inspired by natural antibiotic compounds called
“sideromycins”, which are secondary metabolites comprised of a siderophore moiety and a toxic
cargo. The siderophore part of these compounds is able to scavenge iron and is recognized by
cellular iron-siderophore uptake systems, while the toxic cargo, bearing antibiotic activity, uses
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the siderophore as a “Trojan horse” and exploits the iron-siderophore uptake system as a cellular
entry gate (Miethke & Marahiel, 2007). Microcin E492, produced by a clinical isolate of K.
pneumoniae, is a good example of natural siderophore-antibiotic conjugate. It is an 84-residue
antibacterial peptide with a linearized MGE appended in ester linkage to its C-terminal
carboxylic acid, exhibiting enhanced antibacterial activity against strains expressing siderophore
receptor FepA, Cir, or Fiu (Thomas et al., 2004).
Although inhibition concentrations for some sideromycins are remarkably low, the main
drawback for therapeutical use is the generally high frequency of resistant mutants that have
gained mutations in the iron-siderophore-specific receptors or the TonB complex proteins. In this
respect, synthetic development of sideromycins has proven to be an outgrowing field to generate
a broad array of new antibiotic compounds (Miethke & Marahiel, 2007). The compounds can
generally be produced by derivatizing siderophores and/or antibiotics isolated from cell cultures
(semisynthesis) or by total synthesis. Semisynthesis may be advantageous if suitable functional
groups are provided by the natural compound. However, total synthesis is often preferred since it
allows the rational introduction of useful functional groups at appropriate positions, preferably in
the periphery of the siderophore scaffold. In principle, each structural type of siderophore may be
coupled with each type of antibiotic, yielding a broad spectrum of sideromycin variants. The
siderophore part of the synthesized compounds comprises in most cases hydroxamate,
catecholate, or mixed hydroxamate-catecholate tethered to various backbones. The use of mixligand siderophore that can be taken up via several pathways is seen as advantage since it
reduces the frequency of resistant mutants and, if occurring, makes them more susceptible to iron
starvation since the transport systems are found to be the main targets for resistance formation
rather than the antibiotic targets themselves (Miethke & Marahiel, 2007).
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It is reported that the β-lactam antibiotics ampicillin (Amp) and amoxicillin (Amx) were
linked to a monofunctionalized enterobactin scaffold via a stable poly (ethylene glycol) linker.
Under conditions of iron limitation, these siderophore-modified antibiotics provided enhanced
anti-bacterial activity, compared to the parent β-lactams, against different uropathogenic,
enterohemorrhagic, and enterotoxigenic E. coli strains. Moreover, Ent-Amp and Ent-Amx
selectively killed E. coli co-cultured with other bacterial species such as Staphylococcus aureus,
and Ent-Amp exhibited low cytotoxicity against human intestinal cells in both the apo and ironbound forms (Zheng & Nolan, 2014). In another similar study, a ciprofloxacin (Cipro) cargo was
attached to a synthetic enterobactin platform via an alkyl linker at one of the catechols. It exerted
selective antibacterial activity, comparable to unmodified ciprofloxacin, against pathogenic E.
coli strains. This selectivity was due to that intracellular activation of conjugated Cipro required
the cytoplasmic enterobactin hydrolase IroD, which is expressed only by E. coli that harbor the
iroA gene cluster and are predominantly pathogenic (Neumann et al., 2018).
1.4.2 Artificial iron starvation via competitive metal ions or iron chelators
The artificial iron starvation for bacterial pathogens can be created by iron-competing
metal ions or competitive iron chelators that cannot be utilized by the pathogen. Gallium or
Ga(III) is used in combating bacterial infections because it can compete with Fe(III) in binding
to siderophores, while unable to participate in biologically necessary redox reactions, therefore
arresting metabolic processes that depend on iron-mediated redox reactions (Wilson et al., 2016).
Gallium maltolate, a gallium compound, has been evaluated as a potential therapeutic agent for
methicillin-resistant S. aureus (Baldoni et al., 2010); Gallium nitrate, a commonly used drug for
hypercalcemia, results in antimicrobial activity against multidrug-resistant Acinetobacter
baumannii in vivo and in vitro (Antunes et al., 2012); This FDA-approved drug also inhibits P.
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aeruginosa growth and biofilm formation and kills planktonic and biofilm bacteria in vitro by
decreasing bacterial Fe(III) uptake and interfering with Fe(III) signaling (Kaneko et al., 2007). In
addition, gallium-loaded siderophores present another approach for gallium-based therapeutics.
Pre-loading pyochelin--a siderophore produced by P. aeruginosa--with gallium consistently
leads to a stronger inhibitory effect on P. aeruginosa growth than gallium nitrate in in vitro
bacterial cultures, suggesting treatment with gallium-siderophore complexes could be a more
effective therapeutic option than using simple gallium salts (Frangipani et al., 2014).
Some iron chelators have been found to compete with siderophores for binding Fe(III)
and therefore act as antimicrobial agents. Lactoferrin and other synthetic iron chelators such as
conalbumin, ferric picolinate, ferric acetohydroxamate, 2,2’-dipyridyl (2DP),
diethylenetriaminepentacetic acid (DTPA), EDTA, deferoxamine mesylate (DM), and
ethylenediamine-N,N’-diacetic acid (EDDA) have been shown to reduce growth and biofilm
formation of P. aeruginosa (Saha et al., 2013). Moreover, it is demonstrated that iron chelators
desferroxamine and desferasirox can improve the capability of antibiotic tobramycin to reduce
bacterial biofilms caused by the antibiotic resistant P. aeruginosa in cystic fibrosis cells
(Moreau-Marquis et al., 2009).
1.4.3 Inhibition on siderophore synthesis pathways
The strategy of target-specific siderophore biosynthesis inhibition is proved to be an
attractive research field in recent years due to the availability of crystal structures that allow the
rational design of catalytic site inhibitors. (Miethke & Marahiel, 2007). Most of the studies have
targeted the NRPS which is involved in the synthesis of all aryl-capped siderophores and
requires salicylate (SAL) or DBH as prerequisite precursors. The aryl acid A domain of NPRS
catalyzes the initial step of siderophore formation by activating the aryl acid substrates (SAL or
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DHB) via adenylation. Therefore some inhibitors have been designed to inhibit the catalytic
activity of aryl acid A domain, thus preventing the growth of corresponding pathogens in ironlimited conditions (Saha et al., 2013). Examples of such inhibitors include p-aminosalisylate
(PAS) in M. smegmatis and M. bovis (Brown & Ratledge, 1975) and aryl acid A domain
analogue SAL-AMS (salicyl sulfamoyl adenosine) in M. tuberculosis and Yersinia pestis
(Ferreras et al., 2005). Moreover, siderophore modification processes like tailoring can also be
inhibited. It is shown that brominated enterobactin derivatives are potent inhibitors of IroB, a
bacterial enzyme catalyzing iroA-dependent C-glycosylation of enterobactin in order to evade
the host innate immunity mediated by lipocalin 2. Those IroB inhibitors can potentially be used
as antibiotics against iroA-harboring bacterial pathogens (Lin et al., 2006).
1.4.4 Vaccine development by targeting OMR
In Gram-negative bacteria, OMRs are the “gatekeepers” for cellular uptake of ironsiderophore complex. They display high ligand affinity and specificity (Miethke & Marahiel,
2007). There are considerable studies demonstrating that the OMRs are induced under ironrestricted conditions in vivo and bacterial virulence are attenuated after the genetic knockout of
corresponding genes (Lin et al., 2002), Together, these evidences suggest OMRs as promising
targets for iron starvation and pathogen control. Monoclonal antibody specific for blocking the
FeEnt-binding site of the FeEnt receptor FepA could inhibit the growth of E. coli derived from a
bovine intramammary infection in vitro (Lin et al., 1998). OMRs IreA, Hma, and IutA involved
in iron acquisition of uropathogenic E. coli were utilized as vaccine candidates. Intranasal
immunization of these receptor proteins in mice elicited systemic and mucosal immune response
and provided significant protection from experimental infection of this uropathogenic E. coli
(Alteri et al., 2009). In Campylobacter, CfrA and CfrB, two types of ferric enterobactin receptors
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on outer membrane, are demonstrated to be induced and critical for Campylobacter growth under
iron-limited condition. Antisera directed against CfrA or CfrB could diminish the FeEntmediated in vitro growth promotion under iron-restricted condition (Xu et al., 2010; Zeng et al.,
2009).
Though extensive efforts have been placed on development of vaccines targeting surfaceexposed iron-regulated OMRs, these attempts have had only partial success, primarily due to
complexity of iron acquisition system and redundancy of receptors for utilization of the ferricsiderophore complex in various Gram-negative pathogens. For example, there are up to five
ferric Ent receptors in E. coli (FepA, Cir, Fiu, IroN, and Iha) that show different affinities to Ent
and its derived products. Clearly, such redundancy, together with other issues (e.g., antigenic
variation), raises significant challenges for developing iron-dependent pathogen control by
targeting OMRs (Wang et al., 2019).
1.4.5 Emerging novel siderophore-based intervention
Rather than focusing on iron acquisition-related large cellular targets (e.g., iron-regulated
outer membrane proteins), an innovative ‘out-of-the-box’ strategy focusing on extracellular Ent
siderophore has been inspired by a unique antibacterial function of lipocalins as reviewed above,
and has been supported by a recent study (Sassone-Corsi et al., 2016). It is widely accepted that
huge repertoire of different antibodies can be generated in individual human beings or animals.
In addition, specific high-affinity antibodies could be produced against small molecule (called
‘hapten’) if hapten is conjugated with a carrier protein. Therefore, specific high-affinity
antibodies directed against Ent, a hapten with low molecular mass of 669 Da, could be
theoretically obtained and such Ent-specific antibodies may display a bacteriostatic effect similar
to that observed for lipocalins.
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Recently, intranasal immunization of mice with an enterobactin conjugate vaccine
triggered anti-enterobactin antibodies in the gut mucosa (Sassone-Corsi et al., 2016). When mice
were infected with the enteric pathogen Salmonella, they exhibited reduced intestinal
colonization and reduced systemic dissemination of the pathogen (Sassone-Corsi et al., 2016).
Nevertheless, there are still some weaknesses in this study. The preparation of the enterobactin
conjugate was lengthy and complicated, which required the addition of a linker to enterobactin
for its conjugation with carrier protein; the enterobactin-specific immune response was weak
upon immunization of mice (i.e., <4-fold increase in enterobactin-specific antibodies); it also
failed to provide any direct evidence demonstrating that the induced anti-enterobactin antibodies
could function similarly as lipocalin 2 to interfere with enterobactin-dependent growth
promotion on enteric bacteria under iron-restricted conditions, a critical evidence required for
validating the concept of the enterobactin conjugate vaccine. In another study, yersiniabactin and
aerobactin, the most prevalent siderophores among pathogenic E. coli for iron acquisition, were
utilized as protective vaccine antigens. Intranasal immunization of these siderophore conjugates
elicited an adaptive immune response against the stealth siderophores and reduced bacterial
burdens and inflammation in the urine and kidneys caused by the uropathogenic E. coli (Mike et
al., 2016).

1.5 Egg yolk IgY: a promising alternative to antibiotics for pathogen control
1.5.1 Overview of egg yolk IgY
Hens’ eggs have long been recognized as a rich source of nutrients. It also contains large
quantities of egg yolk antibodies. Immunoglobulin Y (IgY) is the functional equivalent of IgG in
mammals and is selectively transferred from serum to yolk via specific receptor on the surface of
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yolk membrane during egg formation. It therefore provides passive immune protection for the
developing chick. Since the discovery of egg yolk IgY, this process has been harnessed to
produce antigen-specific egg yolk IgY for numerous applications in the medical and production
fields (Kovacs-Nolan & Mine, 2012).
Although the exact mechanisms of action of orally administered IgY remain unclear, it is
well known that they largely depend upon efficient binding of IgY to specific antigens of the
pathogens, thus impairing their growth or biological functions. In the case of bacteria, IgY binds
to structures such as flagella, fimbriae (pili), outer membrane proteins, and lipopolysaccharide
(LPS), and therefore inhibits the bacterial growth, colonization, and/or invasion of host cells
(Gadde et al., 2015). Other mechanisms of IgY include: bacterial agglutination, leading to death
by immobilization and expulsion from the gut; toxin neutralization; inhibition of enzyme
activity; interference of bacterial cellular signaling cascades, reducing bacterial pathogenicity
(Gadde et al., 2015).
There are a number of advantages to using hens for the production of antibodies. First,
when considering antibody production for passive immunotherapy, hens present a much more
economical source of large quantities of specific antibodies. It is shown that an immunized hen
can produce approximately 1500 mg of egg yolk IgY in one month, 2-10% of which is antigenspecific, whereas an immunized rabbit produces 18 times less IgG from serum in the same time
period (Gadde et al., 2015). Second, IgY production is less invasive, only requiring the daily
collection of eggs, compared to blood collection in mammals (Karlsson et al., 2004). Third, in
contrast to mammalian serum, egg yolk contains only a single class of antibody (IgY), which can
easily be isolated from the yolk by precipitation techniques. Meanwhile, IgY does not activate
mammalian complement or interact with mammalian Fc receptors so that it will not mediate
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inflammatory responses when applied to passive immunotherapy in mammals (Kovacs-Nolan &
Mine, 2012). Last but not least, the vaccination of hens and automated collection and processing
of eggs have already been carried out on an industrial scale, making the large-scale production of
IgY technically feasible (Kovacs-Nolan & Mine, 2012).
1.5.2 Stability of egg yolk IgY
The stability of IgY under various processing and physiological conditions is a critical
consideration for passive immunotherapy applications. IgY is fairly stable during storage and
processing. Its stability is not affected by freezing and freeze-drying unless repeated several
times. The activity of IgY is shown to decrease with increasing temperature and time. Minimal
loss of activity was observed following heating between 60 °C and 65 °C but the activity was
decreased markedly by heating for 15 min at 70 °C or higher. However, the addition of
carbohydrates was found to improve its heat resistance. Likewise, it is shown that the addition of
disaccharides or complex carbohydrates to IgY prior to lyophilization could improve the stability
during storage (Kovacs-Nolan & Mine, 2012). IgY is relatively stable between pH 4 and pH 11
but displays a rapid reduction in activity above pH 12 or below pH 3. However, pH stability may
be improved by the addition of stabilizers, such as sugars, complex carbohydrates, and polyols
(Kovacs-Nolan & Mine, 2012). As with any protein, antibodies are susceptible to proteolytic
digestion. IgY is relatively resistant to trypsin and chymotrypsin but quite sensitive to pepsin
digestion, especially at low pH (Gadde et al., 2015).
A major concern for oral immunotherapy application of IgY is the inactivation of IgY
during digestive processes, which depends on gastric pH, enzyme levels, and gastric transit
times. In order to prevent inactivation of IgY following oral administration, a number of
encapsulation techniques have been examined (Kovacs-Nolan & Mine, 2012). The
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macroencapsulation of IgY using enteric-coated gelatin capsules was found to significantly
improve antibody stability (Akita & Nakai, 2000). The use of a pH-sensitive methacrylic acid
copolymer, chitosan-alginate microcapsules, and whey protein-based microcapsules have also
been shown to increase IgY stability to gastric conditions, both in vitro and in vivo (KovacsNolan & Mine, 2012). The use of cytoprotective agent sucralfate is described to be able to
improve IgY resistance to low pH and pepsin treatment, as well as enhance storage stability, in a
dose-dependent manner (Xun et al., 2010). Finding an effective method to protect IgY from
degradation will not only ensure the delivery of viable IgY but could also allow the effective
dose to be lowered, thereby reducing cost.
1.5.3 Applications of hyperimmune egg yolk IgY
The use of hyperimmune egg yolk IgY to prevent and treat human and animal infections
has gained popularity in recent years as an alternative to antibiotic use. Because the absorption of
orally administered egg antibodies is minimal, the majority of applications of egg antibodies are
against enteric infections in both people and animals (Gadde et al., 2015). A recent meta-analysis
study focusing on the therapeutic effects of IgY for enteric infections in domestic animals
concluded that the administration of IgY significantly reduced the risk of infection in the treated
groups compared with that in the untreated controls (Diraviyam et al., 2014).
In veterinary applications, IgY has been proved to prevent a number of bacterial
pathogens and improve growth performance and feed efficiency in livestock. IgY produced
against the porcine enterotoxigenic E. coli fimbrial antigens was demonstrated to protect piglets
from E. coli infection by inhibiting the binding of E. coli to porcine epithelial cells and intestinal
mucus (Yokoyama et al., 1992). More recently, it is found when IgY against enterotoxigenic E.
coli was encapsulated in chitosan-alginate microparticles, it exerted antidiarrheal effects much
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faster and led to increased weight gain when compared to pigs fed with non-encapsulated IgY
(Li et al., 2009). In addition, IgY against the outer membrane proteins of S. enterica and S.
typhimurium reduced Salmonella adhesion to intestinal epithelial cells in vitro (Chalghoumi et
al., 2009). Feeding chickens egg powder containing such IgY was found to reduce fecal
shedding, cecal colonization, and the rate of Salmonella-contaminated eggs in experimentally
infected chickens (Gürtler et al., 2004; Rahimi et al., 2007). Along with preventing diseases, IgY
targeting specific molecules involved in inflammation and animal growth has been reported to
improve growth and feed efficiency in food animals. IgY directed against the gut neuropeptides
cholecystokinin and neuropeptide Y, believed to be involved in regulating appetite and
phospholipase A2 (PLA2), which plays a role in the production of the inflammatory mediators
prostaglandins and leukotrienes, has been shown to improve growth and feed efficiency when
fed to chickens (Cook, 2004; Kovacs-Nolan & Mine, 2012). Similarly, feeding cattle with egg
yolk preparations containing IgY against Fusobacterium necrophorum and Streptococcus bovis
in place of antibiotics could reduce ruminal counts of the target bacteria and improve feed
efficiency and growth performance (DiLorenzo et al., 2008).
In human medicine, one of the most successful clinical applications of IgY is in the
prevention of P. aeruginosa colonization in the airways of cystic fibrosis patients. In the trials of
cystic fibrosis patients, a mouth rinse containing purified anti-P. aeruginosa IgY was given on a
continuous basis and significantly reduced or prevented P. aeruginosa colonization, thereby
reducing the need for antibiotics (Nilsson et al., 2008). Another promising clinical application of
IgY in humans is for the prevention of Helicobacter pylori infection. IgY against H. pylori
reduced bacterial adhesion, growth, and urease activity in vitro and decreased H. pylori-induced
gastric mucosal injury and inflammation in an animal model (Shin et al., 2002). A functional
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drinking yogurt containing Lactobacillus acidophilus and Bifidobacterium spp. and
supplemented with 1% anti-urease IgY was produced commercially and given to volunteers
tested positive for H. pylori. After four weeks, urea breath test values and antigen detection in
feces were significantly reduced, indicating suppression of H. pylori infection (Horie et al.,
2004). The immediate protection afforded by antigen-specific IgY has also been suggested for
protection against agents of bioterrorism. Purified IgY against Clostridium botulinum
neurotoxins type A and B is reported to block the functional activity of the toxins both in vitro
and in vivo in mice following preincubation of the toxin with toxin-specific IgY (Trott et al.,
2009).
In aquaculture, passive immunization of IgY has also been applied to prevent infectious
diseases causing significant economic loss. Edwardsiella tarda is a bacterial pathogen infecting
the intestinal mucosa in fish, and Edwardsiellosis in Japanese eels constitutes a serious problem
for the eel-farming industry. Eels challenged with E. tarda followed by administration of anti-E.
tarda IgY survived without any symptoms of infection, in contrast to control eels that died
within 15 days (Gutierrez et al., 1993). This antibody is now in commercial use, and a field test
on nearly 2,400,000 tails of cultured eels confirmed the disease prevention effect of this anti-E.
tarda IgY (Hatta et al., 2008). Enteric redmouth disease, caused by Y. ruckeri, is a systemic
bacterial septicemia of salmonid fish. The persistence of Y. ruckeri in carrier fish and shedding
of bacteria in feces can cause a continuing source of infection. Feeding anti-Y. ruckeri IgY
before or after bacterial challenge resulted in lower mortality and reduced infection rates in
rainbow trout (Lee et al., 2000). Similarly, IgY against Vibrio anguillarum protected rainbow
trout against vibriosis for at least 14 days when given via intraperitoneal injection, oral
intubation, or feeding (Arasteh et al., 2004).
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Abstract
Enterobactin (Ent)-mediated high affinity iron acquisition is critical for Gram-negative
bacteria to survive in the host. Given the bacteriostatic effect of lipocalin resulting from its
potent Ent-binding ability, immune intervention directly targeting Ent is promising for irondependent pathogen control. Recently, an Ent conjugate vaccine was reported but it still has
several significant weaknesses. In this study, we aimed to develop an innovative Ent conjugate
vaccine that can induce high level of antibodies directed against Ent, and to provide solid
evidence demonstrating siderophore-binding capacity of Ent-specific antibodies. Using a simple
method, we successfully conjugated purified Ent to different carriers including keyhole limpet
hemocyanin (KLH), bovine serum albumin, and CmeC, a vaccine candidate for Campylobacter
control. Subcutaneous immunization of rabbits with the KLH-Ent conjugate triggered strong
systemic IgG immune response with up to 16,384 fold increase in IgG titer directed against
whole conjugate and up to 4,096 fold increase in the level of specific anti-Ent IgG. To evaluate
the binding ability of Ent-specific IgG to the Ent derivatives present in vivo, various Ent
derivatives were chemically synthesized and a unique ELISA method was developed. The Entspecific IgG also displayed exceptional reactivity to ferric Ent, linear trimer of Ent, and different
salmochelins. Growth assays further demonstrated the Ent-specific antibodies significantly
inhibited Ent-dependent growth of Campylobacter spp. and E. coli. Collectively, this study
reports an efficient method to prepare new type of Ent conjugate vaccines for inducing high level
of Ent-specific antibodies, which can bind to various Ent derivatives and display lipocalin-like
bacteriostatic feature.
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2.1 Introduction
All Gram-negative bacteria have an absolute requirement for iron in order to survive and
colonize the host. In animal host, however, iron from various sources is not normally available to
invading bacteria; the concentrations of free iron in vivo are well below the levels required for
the growth of Gram-negative bacteria (Miethke & Marahiel, 2007). To obtain sufficient iron for
survival and multiplication, Gram-negative bacteria have evolved complex and efficient genetic
systems for iron uptake (Miethke & Marahiel, 2007). Of these systems, siderophore (iron
chelator)-meditated high-affinity iron acquisition is the most efficient, widely prevalent, and
highly conserved strategy used by Gram-negative bacteria to scavenge iron in the host (Miethke
& Marahiel, 2007; Skaar, 2010). Enterobactin (Ent), a catecholate siderophore that has the
highest affinity for ferric iron of all natural siderophore compounds, is an archetype for iron
acquisition in Gram-negative bacteria (Raymond et al., 2003). In particular, Ent is produced by
most members of Enterobacteriaceae, the only representative family in the order
Enterobacteriales of the class γ-proteobacteria (Zeng & Lin, 2014). In addition, the hydrolyzed
Ent derivatives (e.g. linear trimer) and the glycosylated Ent derivatives (named as
“salmochelins”) can also be produced and utilized for iron uptake by intestinal commensals and
pathogens (e.g., Escherichia coli and Salmonella enterica) (Miethke et al., 2011; Zeng & Lin,
2014). Therefore, Ent is likely to be used as a significant source of iron for Gram-negative
pathogens during intestinal colonization (Zeng & Lin, 2014). It has been shown that a significant
quantity of catecholate siderophores, primarily Ent, were produced in the intestine and Entmediated iron acquisition played a fundamental role in E. coli colonization in the gut (Pi et al.,
2012).
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Not surprisingly, siderophore-mediated iron acquisition, particularly that mediated
through Ent, has been a historically important research area in bacterial pathogenesis and has
been targeted for developing various iron-dependent pathogen control strategies. In the past
decades, extensive efforts have been placed on development of specific siderophore biosynthesis
inhibitors and the vaccines targeting surface-exposed iron-regulated outer membrane proteins
(Lin et al., 2002; Miethke & Marahiel, 2007). However, these approaches have had only partial
success, primarily due to complexity of siderophore synthesis and redundancy of systems for
utilization of the ferric-siderophore complex in various Gram-negative pathogens. For example,
there are up to five ferric Ent receptors in E. coli (FepA, Cir, Fiu, IroN, and Iha) that show
different affinity to Ent and its derived products (Curtis et al., 1988; Hantke et al., 2003; Léveillé
et al., 2006; Nikaido & Rosenberg, 1990; Pierce et al., 1983). Clearly, such redundancy together
with other issues (e.g., antigenic variation) raises significant challenges for developing irondependent pathogen control by targeting outer membrane proteins.
Rather than focusing on iron acquisition-related large cellular targets (e.g., iron-regulated
outer membrane proteins), an innovative ‘out-of-the-box’ strategy focusing on extracellular Ent
siderophore has been inspired by a unique antibacterial function of lipocalins (Clifton et al.,
2009; Flo et al., 2004; Santos et al., 2009; Wu et al., 2010; Xiao et al., 2017), and further
supported by a recent study on evaluation of an Ent conjugate vaccine (Sassone-Corsi et al.,
2016). Lipocalins are host acute phase proteins secreted by neutrophils and epithelial cells during
inflammation and rapid cell growth. In addition to their important and pleiotropic functions in
diverse cellular processes in the host, which are unrelated to antibacterial activity, lipocalins
have been demonstrated to be involved in the antibacterial iron depletion strategy of the innate
immune system (Clifton et al., 2009; Flo et al., 2004; Santos et al., 2009; Wu et al., 2010; Xiao et
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al., 2017). Specifically, lipocalins inhibit E. coli and other Gram-negative infections by binding
Ent with high affinity, thus functioning as bacteriostatic agents controlling the growth of bacteria
in which Ent-mediated iron acquisition plays an important role in pathogenesis (Clifton et al.,
2009; Flo et al., 2004; Santos et al., 2009; Wu et al., 2010; Xiao et al., 2017). The bacteriostatic
function of lipocalins has provided a strong rationale for developing lipocalin-like Ent-binding
protein to inhibit Ent-mediated iron acquisition in Gram-negative bacteria. It is widely accepted
that huge repertoire of different antibodies can be generated in individual human beings or
animals. For example, it has been estimated that humans are able to generate about 10 billion
different antibodies, each capable of binding a distinct epitope of an antigen (Fanning et al.,
1996). In addition, specific high-affinity antibodies could be produced against small molecule
(called ‘hapten’) if hapten is conjugated with a carrier protein (Clementi et al., 1991). Therefore,
specific high-affinity antibodies directed against Ent, a hapten with low molecular mass of 669
Da, could be theoretically obtained and such Ent-specific antibodies may display a bacteriostatic
effect similar to that observed for lipocalins. This speculation has been partly supported by a
recent publication showing an Ent conjugate vaccine inhibited Salmonella colonization in mice
(Sassone-Corsi et al., 2016). Nevertheless, in this recent study, preparation of Ent conjugate was
lengthy and complicated, which required addition of a linker to Ent for its conjugation with
carrier protein (Sassone-Corsi et al., 2016). In addition, the Ent-specific immune response was
weak upon immunization of mice with the Ent conjugate (< 4 fold increase in Ent-specific
antibodies) (Sassone-Corsi et al., 2016), highlighting the needs to develop new type of Ent
conjugate that is capable of inducing high levels of Ent-specific antibodies. Finally, SassoneCorsi et al. (Sassone-Corsi et al., 2016) did not provide microbiological and biochemical features
of anti-Ent antibodies in terms of their binding capability to catecholates and effectiveness for
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iron sequestration when compared to lipocalins, a critical issue that needs to be addressed to test
the hypothesis.
In this study, using a simple and efficient protocol, we successfully conjugated purified
Ent to keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA), and CmeC, a
promising subunit vaccine candidate for Campylobacter control (Zeng et al., 2010).
Immunization of rabbits with the KLH-Ent conjugate triggered strong immune response, leading
up to 4,096-fold increase in the level of specific anti-Ent immunoglobulin G (IgG) in serum. For
the first time, we also observed that the Ent-specific IgG displayed potent binding ability not
only to both apo and ferric Ent (FeEnt) but also to other Ent derivatives including salmochelins,
indicating the Ent-specific antibodies induced by the KLH-Ent conjugate vaccine overcome a
significant pitfall of the host innate immune component lipocalin that has low affinity to
salmochelins. In another word, the Ent antibodies have a significant advantage over lipocalins by
cross-reacting to various Ent derivatives including salmochelins. Finally, we demonstrated that
the rabbit Ent antiserum displayed significant inhibitory effect on Ent-dependent growth of
Campylobacter and E. coli.

2.2 Materials and methods
2.2.1 Bacterial strains and culture conditions
The bacterial strains used in this study are listed in Table 1. Campylobacter strains were
routinely grown in Mueller-Hinton (MH) broth (Difco, Detroit, MI) or on MH agar (Difco) at
42 °C in a microaerophilic incubator (5% O2, 10% CO2, and 85% N2). E. coli strains were grown
in Luria-Bertani (LB) broth (Difco) or TSB broth (Difco, Detroit, MI) with shaking (200 rpm) or
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on agar at 37 °C. When needed, culture media were supplemented with kanamycin (30 μg/ml) or
tetracycline (15 μg/ml).
2.2.2 Purification of Ent
An Ent transport mutant of E. coli AN102 (JL122, Table 1) was generously provided by
Dr. Sandra K. Armstrong (University of Minnesota) and used for Ent purification. The
purification procedure was described previously (Anderson & Armstrong, 2004; Zeng & Lin,
2017). The purified Ent was dissolved in methanol or DMF, and stored at -20 °C until it was
used.
2.2.3 Conjugation of Ent with carrier proteins
BSA and KLH were purchased from Thermo Fisher Scientific (Waltham, MA).
Recombinant CmeC was purified as described in a previous study (Zeng et al., 2010). A standard
protocol was developed by examining various conjugation parameters, such as concentration,
temperature, organic solvents, and reaction time. Briefly, 45 µl BSA, KLH or CmeC (1.0 µg/ml)
was dissolved in 360 µl sodium phosphate buffer (0.1 M, pH 8.0). To this solution, 45 µl of Ent
(50 mM in DMF) was added. The mixture was incubated at 37 °C for 4 hrs, followed by buffer
exchange using Amicon Ultra-4 Centrifugal Filter Units (MilliporeSigma, St. Louis, MO) with
ddH2O three times and PBS buffer (pH 7.4) six times. Each batch of Ent conjugates were
subjected to SDS-PAGE analysis to validate the success of conjugation. Finally, Ent conjugates
(~1 mg/ml in PBS) were stored at -20 °C prior to use.
2.2.4 Immunization of rabbits with the KLH-Ent conjugate
Two independent immunization trials (two rabbits per trial) were performed in 2013 and
2016, respectively, by Pacific Immunology Corp. (Ramona, CA). The vaccination regimen was
same for the two trials except that a 4-week extension was added in the second trial to collect
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more antisera. Briefly, adult New Zealand white rabbits received primary immunization via
subcutaneous administration (in the area between the shoulders) with 100 µg of KLH-Ent
conjugate emulsified with Freund’s complete adjuvant, followed by three booster immunizations
(100 µg of KLH-Ent conjugate emulsified with Freund’s incomplete adjuvant) every 3-4 weeks.
Blood samples were collected at different time points. Rabbits were euthanized at 14th week or
18th week for the first trial and second trial, respectively, after the primary immunization.
2.2.5 Immunoblotting
To validate production of rabbit polyclonal anti-Ent IgG, Western blotting and dot
blotting were performed as described previously (Sahin et al., 2001; Zeng et al., 2009). For
Western blotting, protein samples were first separated by SDS-PAGE with a 12% (w/v)
polyacrylamide gel and then electrophoretically transferred to nitrocellulose membranes (BioRad, Hercules, CA) at 90V for 1 hr. For dot blotting, approximately 1 µl of protein sample (1
mg/ml) was spotted onto nitrocellulose membranes and air dried. Subsequently, the
nitrocellulose membrane was incubated with the blocking buffer (PBS containing 0.05% of
Tween 20 and 5% of skim milk) at room temperature (22 °C) for 1 hr, prior to 1-hr incubation at
room temperature with primary antibodies (1:100 diluted polyclonal rabbit anti-Ent serum in
blocking buffer). After incubation, the membranes were washed four times with PBS containing
0.05% Tween 20 and then incubated with secondary antibody (goat anti-rabbit IgG-horseradish
peroxidase, SeraCare, Milford, MA; diluted 1:5000 in blocking buffer) for 1 hr at room
temperature. After incubation the membranes were washed four times with PBS containing
0.05% Tween 20. The membranes were then developed with the 4CN Membrane Peroxidase
Substrate System (KPL, Gaithersburg, MD).
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2.2.6 Purification of His-tagged recombinant proteins
The His-tagged recombinant IroE, IroB, human lipocalin-2, and CmeC were purified
from JL633, JL636, JL1002, and JL243 (Table 1), respectively, as detailed in previous
publications (Fischbach et al., 2005; Garénaux et al., 2013; Lin et al., 2005). Notably, the
recombinant human lipocalin-2 was produced in an Ent deficient strain (ΔentD), ensure that the
purified lipocalin was not bound by endogenous Ent. The high purity of the recombinant proteins
was confirmed by SDS-PAGE. The concentration of purified recombinant protein was
determined using bicinchoninic acid (BCA) assay (Thermo Fisher Scientific). The purified
recombinant protein was aliquoted and stored at -20 °C prior to use. With respect to human
lipocalin-2 used for growth assay described below, the protein was dialyzed against PBS,
sterilized by membrane filtration (0.22-μm filter), and stored at -20 °C prior to use.
2.2.7 Synthesis and purification of Ent derivatives
The ferric Ent complex was prepared by mixing Ent with 1.2 equivalent of FeCl3 as
described by Zeng et al. (Zeng et al., 2013). Linearized DHBS trimer was produced by
hydrolysis of Ent by recombinant IroE followed by HPLC purification as described in our
previous publication (Zeng et al., 2013). Salmochelins (MGE, DGE, and TGE) were synthesized
by Ent glucosylation and purified with HPLC as described in our previous work (Fischbach et
al., 2005; Lin et al., 2005) with slight modifications. Briefly, 500 μl of reaction mix contains 75
mM Tris buffer (pH 7.5), 5 mM MgCl2, 2.5 mM TCEP-HCl, 3 mM UPD-Glc, 500 μM Ent, and
1 μM IroB. At different time points, the reaction was stopped by adding 0.1% TFA and analyzed
by HPLC using a gradient of 0-43.75% CH3CN in 0.1% TFA water over 10 minutes. Fractions
of MGE, DGE, and TGE were collected, lyophilized, and stored at -20 °C prior to use.
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2.2.8 TLC-Immunostaining
The TLC of Ent was performed as described in our previous publication (Zeng et al.,
2013). In brief, 1 μl of the Ent solution (10 mM, dissolved in methanol) was spotted in TLC
plate (Whatman PE silica gel with UV) and developed with benzene:acetic acid:water (110:85:5)
(v/v). The immunostaining was performed by following the protocol described by Duvar et al.
(Duvar et al., 1997). The silica gel was fixed with 0.5% polyisobutylmethacrylate (Polysciences,
Inc., Warrington, PA), which is dissolved in chloroform:n-hexane (1:9), and dried in chemical
fume hood. The silica gel was incubated in blocking solution (PBS containing 5% of skim milk)
for 1 hr at room temperature, followed by incubation with anti-Ent antibodies (1:100 dilution of
rabbit polyclonal Ent antiserum in blocking solution) with gentle shaking for 1 hr. Subsequently,
the silica gel was washed five times with washing buffer (PBS containing 0.05% Tween 20), and
incubated with secondary antibodies (goat-anti-rabbit IgG-HRP, Seracare; 1:2000 dilution in
blocking solution) for 1 hr at room temperature. After incubation the silica gel was washed as
described above. The silica gel was developed for visualization by using SuperSignal West Dura
Chemiluminescent Substrate (Thermo Fisher Scientific).
2.2.9 ELISA
Indirect ELISA were conducted as described previously with modifications (Zeng et al.,
2010) to examine IgG response in rabbit sera against KLH-Ent (to measure the general antibody
response), BSA-Ent (to measure the Ent-specific antibody response), as well as different Entderivative compounds (to evaluate the binding specificity of Ent-specific IgG). The ELISA
plates were coated differently depending on specific purpose. To determine the titer of general
serum IgG directed against the KLH-Ent conjugate, microtiter plates (Thermo Fisher Scientific)
were coated with 100 μl of KLH-Ent (30 ng/well) in coating buffer (bicarbonate/carbonate
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coating buffer, pH 9.6) overnight at room temperature. To measure the level of Ent-specific IgG
in rabbit sera, 100 μl of BSA-Ent (30 ng/well) was coated onto microtiter plates using the same
coating method as described above.
To further validate the titer of anti-Ent IgG and particularly evaluate the binding ability of
the Ent-specific IgG to different Ent derivatives, Ent or its derivatives was directly coated onto
ELISA plates using a unique coating method based on an early publication (Bantroch et al.,
1994) with modifications. In brief, Ent and its derivatives were diluted in methanol to final
concentration of 0.5 mM and added in ELISA plate (20 μl/well). Subsequently, the ELISA plates
were placed on a hotplate (set at 60 °C) in chemical fume hood for 30 min for complete
evaporation of methanol due to mild heat and airflow. Upon completion of specific coating
procedure as described above, the dried ELISA plates with directly coated small compounds
were subjected to standard ELISA test as described in a previous publication (Sahin et al., 2001)
with slight modifications. Serum sample was serially diluted by up to 4,096-fold for ELISA
analysis. The secondary antibody goat anti-rabbit IgG labeled with horseradish peroxidase
(SeraCare) was diluted 1:1000 in blocking buffer and 100 μl was added to each well. After 1-hr
incubation, plates were washed three times. Then plates were developed using the ABTS
Peroxidase Substrate Kit (KPL) and the reaction was stopped after 30 min using 100 μl stopping
solution (1X PBS, 1% SDS). Absorbance was measured at optical density of 405 nm (OD405)
using an ELX808 (BioTek Instruments, Inc., Winooski, VT) and data were collected using Gen5
software version 2.03.1 (BioTek Instruments, Inc.). The wells without addition of primary
antibody served as background control. Endpoint titer was defined as the last dilution at which
OD405 of sample wells exceeded the cutoff value (mean OD405 plus 3 × standard deviation of
preimmune sera at 512-fold dilution). Titer was expressed as the reciprocal of the end point
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dilution log2. Duplicate or triplicate independent measurements were performed for each serum
sample.
2.2.10 Ent growth promotion assay
The inhibitory effect of anti-Ent IgG on Ent-dependent growth of Campylobacter was
evaluated using a modified growth promotion assay as described in previous publication (Zeng et
al., 2009). The C. jejuni JL241 and C. coli JL170 (Table 1) were selected as representative
strains in this assay. Prior to the assay, both rabbit control and Ent antisera were heat-inactivated
at 56 °C for 30 min to abolish complement activity, followed by dialysis against PBS and
sterilization via membrane filtration (0.22-μm filter). The sterile rabbit sera were stored at 4 °C.
Briefly, C. jejuni log-phase cells grown in MH broth (~ 1 x 107 cells) were mixed with melted
MH agar (0.6% agar) supplemented with chelator Desferoxamine (DFO, final concentration of
20 µM), as well as PBS, control serum (final 5.6-fold dilution), Ent antiserum (final 5.6-fold
dilution), or human lipocalin-2 (final concentration of 24 µg/ml). The mixture was immediately
poured into small petri dishes (6 cm of diameter) for solidification. A sterile paper disc (6 mm
diameter) containing 10 μl of Ent (10 mM) was placed onto the surface of each agar plate.
Bacterial growth zones surrounding the disks were observed and measured after 24 hrs of
incubation at 42 °C under microaerophilic condition. The experiment was performed in triplicate
for each treatment.
2.2.11 In vitro growth assay
The inhibitory effect of anti-Ent IgG on the growth of E. coli K-12 strain MG1655 under
iron-restricted condition was evaluated using a microtiter growth assay as described in previous
publications (Garénaux et al., 2013; Lin et al., 1998) with slight modifications. Briefly, E. coli
MG1655 was inoculated into the TSB broth supplemented with 0.6 mM of α,α’-dipyridyl. The
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log-phase cells were washed two times with sterile PBS and subsequently diluted with RPMI
medium (Gibco, Dublin, Ireland) to final concentrations about 5 x 105 CFU/ml. In microplate
wells, 150 μl of RPMI medium was mixed with 50 μl of control serum, 50 μl of Ent antiserum,
or 50 μl of control serum plus 10 μl of stock human lipocalin-2 (0.8 mg/ml). Subsequently, 5 μl
of above bacterial inoculum cells were added into each well. The microplate was incubated at
37 °C for up to 24 hrs. At different time points (8 hrs, 18 hrs, and 24 hrs post-inoculation,
respectively), 20 μl of culture was taken from each well, serially diluted in ice-cold RPMI
medium, and plated onto LB agar plates. The CFU number was enumerated after overnight
growth and in vitro growth was expressed as log10CFU/ml. Each treatment group was performed
in duplicate.
2.2.12 Statistical analysis
Statistical analyses were conducted using a t-test with two-tailed distribution and paired
sample. Data were presented as mean ± standard deviation. A probability level of P<0.05 was
considered as a statistically significant difference.

2.3 Results
2.3.1 Conjugation of Ent with carrier proteins
We first conjugated Ent to KLH and BSA, the two immunogenic and commonly used
carrier proteins. Notably, these two carrier proteins display significant sequence divergence;
therefore, corresponding antibodies lack any cross-reactivity between the two carrier proteins,
providing an easier way to validate the production of Ent-specific IgG as described below.
Based on structural analysis and current knowledge in organic chemistry, we observed
that Ent could be conjugated to the target carrier protein through one feasible chemical reaction.
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Specifically, the ester groups in Ent theoretically could react with the Lys side chains in BSA
and KLH if the carrier proteins were incubated with Ent under appropriate conditions; a
linearized 2,3-dihydroxybenzoylserine (DHBS) trimer would be attached to the carrier protein
(Figure 1A). We also speculated that the surface-exposed linear DHBS trimer on carrier protein
might lead to effective antigen presentation upon immunization, consequently inducing high
level of antibodies directed against Ent. Regarding BSA that contains 59 lysine residues in each
molecule, approximately 35 of which have exposed primary amines that are capable of coupling
Ent. Each molecule of KLH contains hundreds of primary amines available for coupling Ent.
Therefore, under proper reaction conditions, Ent may directly react with amines in a carrier
protein to form a covalent bond (Figure 1A).
The high-purity Ent was extracted from an Ent transport mutant of E. coli with yield
about 100 mg of Ent/5 L culture using a standard protocol (Anderson & Armstrong, 2004; Zeng
& Lin, 2017). The purity of Ent has been routinely validated by HPLC method as described in
this study and in our previous publication (Zeng et al., 2013); no any organic molecules were
detected to be co-purified along with Ent. We examined different parameters, such as Ent
concentration, pH, temperature, and solvent, to optimize efficiency and consistency of
conjugation of Ent to BSA and KLH. Initially, to conjugate Ent with BSA, we chose phosphate
buffer (pH 8.0) as the reaction buffer. At 4 °C, the conjugation could not be completed even after
overnight reaction (12 hrs). However, the labeling reaction worked well at 37 °C as indicated by
the smear of bands with higher molecular mass (Figure 2A, lanes 2 & 3) than unlabeled BSA
when less than 20% of methanol was used in reaction mix. To avoid potential cross conjugation,
we intended to ensure saturated conjugation specifically by taking the ratio of Lys residue of
BSA and Ent into account; the lowest ratio we tested (63:1) worked well (Figure 2A). Different
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organic solvents, which included methanol, dimethyl sulfoxide (DMSO), and
dimethylformamide (DMF), were used to dissolve Ent for preparation of stock solution;
however, no obvious effect of solvent choice on the conjugation reaction was observed. Finally,
we determined that 2-4 hrs of reaction time at 37 °C was the best condition for the conjugation of
Ent to the carrier protein. Scale-up using the optimized conditions also led to successful
conjugation of Ent to BSA and KLH (Figure 1B). Specifically, the 4-hr conjugation of Ent with
KLH led to significant shift and smear when compared to control KLH (Figure 1B, left panel). A
similar band shift was also observed for conjugation of Ent with BSA (Figure 1B, middle panel).
To examine the commonality of the simple conjugation method when using different carrier
protein, we chose CmeC, a subunit vaccine candidate that has 36 surface-exposed Lys residues
(Su et al., 2014; Zeng et al., 2010) as a carrier. As shown in Figure 1B (right panel), a significant
smear was also observed after the 4-hr conjugation of Ent with CmeC.
Successful conjugation of Ent to KLH (KLH-Ent), BSA (BSA-Ent), or CmeC (CmeCEnt) was further validated by using the antiserum from rabbits immunized with the KLH-Ent
conjugate. Both dot blot (Figure 3A) and standard Western Blot (Figure 3B) demonstrated
successful conjugation of Ent to different carrier proteins using the same straightforward
protocol. As expected, the antiserum could react with both KLH and KLH-Ent conjugate (Figure
3A). Due to significant sequence divergence between KLH and BSA, the antiserum raised by
KLH-Ent did not cross-react with BSA (Figure 3A). However, the antiserum reacted with BSAEnt vividly, demonstrating the presence of Ent-specific antibodies in the antiserum raised by
KLH-Ent conjugate (Figure 3A). The finding from dot blot was further confirmed by Western
blotting analysis of comparable amount of carrier protein and its corresponding Ent conjugate.
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As shown in Figure 3B, the serum from the rabbit immunized with KLH-Ent failed to detect
BSA or CmeC carrier proteins but reacted with both BSA-Ent and CmeC-Ent conjugates.
2.3.2 KLH-Ent conjugate vaccine elicited significant immune response and high level of
Ent-specific IgG
Vaccination of rabbits with the KLH-Ent conjugate triggered strong systemic immune
response, which was confirmed in two independent trials with two rabbits in each trial. With
respect to IgG immune response against the whole KLH-Ent conjugate, upon primary and two
boost immunizations, the ELISA titer of serum IgG directed against the KLH-Ent conjugate in
each rabbit was drastically elevated by 11-14 log2 units (or 2,048-16,384 fold increase) at week 7
postimmunization (Figure 3C). The high-level of IgG titer was maintained throughout the
remaining period by week 10 postimmunization when the third boost immunization was
performed (Figure 3C). However, the third boost immunization did not further enhance the titer
of IgG directed against KLH-Ent (Figure 3C). The dynamic change and pattern of the titer of
IgG directed against KLH-Ent were similar among the four individual rabbits (designated as R1,
R2, R3, and R4; Figure 3C).
To determine specific immune response directed against the small Ent molecule, ELISA
was performed by coating ELISA plates with the BSA-Ent conjugate. In general, immunization
of rabbits with the KLH-Ent significantly induced Ent-specific IgG in each rabbit (up to 11 log2
units or 2,048 fold increase); however, the dynamic change and pattern of anti-Ent IgG titer
displayed great variation among the four individual rabbits (Figure 3D). For example,
immunization of R2 elevated specific anti-Ent IgG in serum by 8 log2 units at week 7
postimmunization; the subsequent third boost immunization at week 10 further increased level of
anti-Ent IgG titer at week 13 postimmunization, leading to total 2,048 fold increase in the level
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of Ent-specific IgG (Figure 3D). In other three rabbits (R1, R3, and R4), the magnitude of
increase in the titer of anti-Ent IgG upon KLH-Ent immunization was smaller than that observed
in R2 rabbit (Figure 3D). When increasing concentration of the coated BSA-Ent antigen from 30
ng/well to 2 μg/well for ELISA analysis, we observed more consistent basal IgG titer in
preimmune sera (7 log2 units) and larger magnitude of increase in the titers of Ent-specific IgG in
postimmune sera in majority of rabbits, which were 5, 12, 8, and 5 log2 units increase for R1, R2,
R3, and R4, respectively (Figure 3E).
2.3.3 The anti-Ent IgG can bind to various Ent derivatives
Due to the high diversity and flexibility nature of antibodies, the Ent-specific antibodies
triggered by the KLH-Ent conjugate may display broad binding spectrum not only for apo Ent
but also for FeEnt complex as well as various Ent derivatives including salmochelins, the
glycosylated Ent that helps enteric pathogens counteract sequestration of siderophores by host
lipocalins (16). To test this, we synthesized a panel of Ent derivatives in vitro followed by
successful validation of the binding ability of Ent antibodies to these catecholate compounds
using a modified ELISA method.
Both FeEnt and linearized DHBS trimer were synthesized using a standard procedure as
described in our previous publication (Zeng et al., 2013). To produce the three different
salmochelins (mono-, di-, and tri-glucosyl Ent, denoted as MGE, DGE, and TGE, respectively),
the high-purity IroB, a C-glycosyltransferase, was first purified from E. coli JL 636 strain (Table
1, Figure 4A). Subsequently, the three salmochelins were in vitro synthesized using Ent and IroB
enzyme as described previously (Fischbach et al., 2005) followed by HPLC purification. As
expected, HPLC displayed three characteristic peaks, representing three different salmochelin
products (Figure 4B).
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After obtaining the Ent derivatives, we initially performed Thin Layer Chromatography
(TLC)-Immunostaining that was expected to provide direct and sensitive evidence showing
interaction between specific catecholates and anti-Ent antibodies. However, in terms of positive
control Ent, we failed to detect chemiluminescent signal although the cyclic Ent was separated
well with TLC as observed in our previous study (Zeng et al., 2013). Given this technical issue,
we subsequently developed an indirect ELISA to evaluate the binding ability of Ent-specific IgG
to various Ent derivatives. Notably, the conventional coating solution for ELISA, such as the
bicarbonate/carbonate buffer (pH 9.6), is not suitable to effectively coat Ent and its relevant
catecholates, the hydrophobic compounds, on ELISA plate. Therefore, based on an early
publication by Bantroch et al. (Bantroch et al., 1994), we developed a unique coating method by
using organic solvent methanol as coating solution to coat catecholate siderophores on ELISA
plate. As shown in Figure 5, the ELISA plates coated with Ent (10 nmol/well) or the BSA-Ent
conjugate (2 μg/well) showed the same level of Ent-specific IgG for preimmune and postimmune
sera, respectively; this finding is consistent and has been confirmed in at least two independent
experiments. Thus, the modified method for direct coating of ELISA plate with Ent is reliable,
simple, and straightforward to detect the binding ability of IgG against hydrophobic small
compounds, such as catecholates, using indirect ELISA.
As shown in Figure 6, compared to preimmune serum, the rabbit Ent antiserum clearly
displayed binding ability to Ent and various derivatives even if the serum was diluted by 4,096
folds. The rabbit antiserum showed comparable binding to apo Ent, linear Ent trimer, and
salmochelins MGE and DGE (Figure 6). However, regarding TGE, the Ent modified with three
glycosyls (Figure 7), the Ent antiserum showed reduced binding capability. Interestingly, the
anti-Ent antibodies raised by the KLH-Ent conjugate in this study consistently showed enhanced
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binding for FeEnt complex when compared to the binding for original hapten Ent (Figure 6).
With respect to DHBA, a small siderophore considered as Ent precursor (Figure 7) (O'Brien et
al., 1970), the anti-Ent antibodies failed to detect it even if the coating concentration of DHBA
was increased by 3 fold accordingly due to monomer unit nature of DHBA, suggesting low
binding of the anti-Ent antibodies to DHBA.
2.3.4 Ent-specific antibodies inhibited Ent-mediated growth promotion in Campylobacter
We speculated that Ent-specific antibodies could function as lipocalin-like agent to
inhibit Ent-mediated iron uptake and bacterial growth. Campylobacter serves as an ideal
organism to test this hypothesis because this organism lacks ability to synthesize any
siderophores and shows low redundancy of iron acquisition systems (Zeng & Lin, 2014), Thus,
using standard Ent growth promotion assay and a purified human lipocalin-2 (Figure 8A) as
positive control, we initially examined the effect of Ent-specific antibodies on Ent-mediated
growth promotion in JL170 and JL241 (Table 1), the representative C. coli and C. jejuni strains
for FeEnt acquisition study in Campylobacter (Naikare et al., 2013; Xu et al., 2010; Zeng et al.,
2013; Zeng et al., 2009).
As shown in Figure 9A, the Ent antiserum displayed significantly inhibitory effect on
Ent-dependent growth of C. coli JL170; the diameter of growth zone for anti-Ent rabbit serum
(3.32±0.10 cm) is significantly smaller than those for control serum (3.85±0.10 cm, P=0.02) and
PBS control (3.68±0.03 cm, P=0.03). As expected, the zone size (2.57±0.03 cm) for the purified
human lipocalin-2, the positive control, is significantly smaller (P=0.01) than those for any other
treatments including Ent antiserum (Figure 9A). However, for C. jejuni NCTC 11168 (JL241),
the zone size is not different between control serum and Ent antiserum (Figure 8B). Because the
same concentration of human lipocalin-2 did not exert inhibitory effect on the growth of
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NCTC11168 either (Figure 8B), we speculated C. jejuni NCTC 11168 was less sensitive than C.
coli JL170 for the interference of iron acquisition resulting from Ent-binding proteins. Thus, the
quantity of Ent-specific antibodies might not be high enough to exert inhibitory effect on FeEntmediated iron acquisition in C. jejuni NCTC 11168. To test this, we modified growth promotion
assay by increasing the volume of control serum or Ent antiserum in soft agar, which showed the
Ent antiserum significantly inhibited the growth of C. jejuni NCTC 11168 when compared to
control serum (P=0.03) and PBS (P=0.02) (Figure 9B).
2.3.5 Ent-specific antibodies inhibited Ent-dependent growth of E. coli
The E. coli MG1655 was subsequently used as a representative Ent-producing strain to
examine the inhibitory effect of the Ent-specific antibodies on bacterial growth under ironrestricted conditions. In the presence of control serum, the E. coli MG1655 strain displayed
normal growth by reaching approximately 10 log units by 18 hrs (Figure 10). In contrast, the E.
coli MG1655 barely grew in the presence of Ent antiserum; by 18 and 24 hrs, the concentration
of the E. coli MG1655 was less than the original level at 0 hr (Figure 10). As expected, the
lipocalin 2 also showed potent and similar bacteriostatic effect on the growth of the E. coli strain
as Ent antiserum (Figure 10).

2.4 Discussion
Sassone-Corsi et al. (Sassone-Corsi et al., 2016) recently reported an Ent-based conjugate
vaccine with the same concept but using different design and synthesis procedure. Specifically, a
different carrier protein – cholera toxin subunit B (CTB) – was chosen for conjugation due to its
adjuvant feature to induce mucosal immune response. In addition, with aid of a PEG3 linker
attached to Ent, which resulted from a stepwise chemical synthesis and modifications, the Ent
was covalently attached to the surface-exposed Lys residues of CTB, leading to the CTB-Ent
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conjugate that harbors the native Ent scaffold (Sassone-Corsi et al., 2016). Immunization of mice
via intranasal route with the CTB-Ent conjugate was observed to generate mucosal IgA directed
against Ent; however, the specific immune response was weak because anti-Ent IgA level was
only slightly increased (< 4 fold) upon CTB-Ent vaccination (Sassone-Corsi et al., 2016). In
addition, Ent-specific antibodies (e.g., anti-Ent IgG) were not detected in systemic system (blood
and spleen) upon immunization of mice with the CTB-Ent. Thus, new type of conjugative Ent
vaccine with simple synthesis procedure and capability to induce strong Ent-specific immune
response is highly warranted. Finally, despite moderate protection conferred by the CTB-Ent
conjugate against Salmonella colonization in mice, Sassone-Corsi et al. (Sassone-Corsi et al.,
2016) did not provide any evidence demonstrating the induced anti-Ent antibodies could function
similarly as lipocalin to interfere with Ent-dependent growth promotion in enteric bacteria under
iron-restricted conditions, a critically important evidence required for validating the concept of
the Ent conjugate vaccine. Here we reported a new type of Ent conjugate (Figure 1), which was
synthesized by direct incubation of carrier protein with Ent for 2-4 hrs, can induce strong
systemic immune response and increases specific anti-Ent IgG level by up to 4,096 fold (Figure
3). We also developed a unique coating method for ELISA and provided direct evidence that
anti-Ent IgG has strong binding ability to various Ent derivatives (Figure 6). We further
demonstrated that rabbit Ent antiserum did exert significant inhibitory effect on Ent-dependent
growth of two representative Gram-negative organisms under iron-restricted conditions (Figure 9
and Figure 10).
In the study by Sassone-Corsi et al (Sassone-Corsi et al., 2016), it was noted that the
modified cyclic Ent was further chelated with ferric iron prior to conjugation with CTB. Clearly,
the FeEnt complex displays a distinct and more compact configuration when compared with apo
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Ent (Figure 7). This evidence together with the modification of Ent with a PEG3 linker likely
interferes with proper antigen presentation to stimulate and select desired antibodies targeting
Ent epitope, which may explain the weak Ent-specific immune response observed upon CTB-Ent
vaccination (Sassone-Corsi et al., 2016) even if CTB has been widely demonstrated for its potent
ability to induce a strong immune response as an adjuvant. In contrast, the Ent conjugate
developed in this study is based on direct chemical reaction between surface exposed Lys of
carrier protein and Ent (Figure 1); the Ent linked to the carrier is expected to be in the form of
linear trimer (DHBS)3 (Figure 1A and Figure 7). Based on such design, we have speculated that
the Ent conjugate may trigger strong and specific immune response directed against the
conserved Ent epitope(s) and such anti-Ent antibodies may even display broad spectrum to bind
to various Ent derivatives, which have been tested and demonstrated in this study. Based on the
straightforward principle of Ent conjugation adopted in this study (Figure 1A), it is important to
mention that Ent is expected to be conjugated to diverse carrier proteins that have exposed Lys
residues, such as subunit vaccine candidates and mucosal carrier/adjuvant, consequently
generating innovative multivalent vaccines. This speculation has been partly tested and
supported by the successful conjugation of Ent to CmeC, a promising subunit vaccine candidate
for Campylobacter control (Figure 1B and 3B).
The finding from this work also strongly supports our hypothesis that the Ent antibodies
may have a significant advantage over host lipocalins in terms of sequestration of various
catecholate siderophores. The Ent antibodies elicited by the KLH-Ent have binding ability to a
panel of structurally similar catecholates, which include FeEnt complex, linear Ent trimer, and
salmochelins (MGE, DGE, and TGE). The anti-Ent IgG also displayed higher binding ability to
FeEnt complex when compared to the binding to apo Ent (Figure 6), a noteworthy feature
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resulting from our conjugation method (Figure 1). Recently, molecular structure of FeEnt was
revealed by a Racemic crystallography (Johnstone & Nolan, 2017), which will help us
understand the delicate interaction between Ent and its specific antibodies. Our study also
showed that too many modifications on Ent could compromise the recognition of the Entspecific antibodies, as reflected by the relatively low binding of ant-Ent IgG to TGE (Figure 6).
To develop effective Ent conjugate vaccine, it is important to put the bacteriostatic effects
of the antiserum into biological context. In this proof-of-concept study, large quantity of Ent
antisera was used in the in vitro growth assays, which may raise a concern regarding relative
potency of the antisera compared to a biologically relevant concentration of lipocalin 2.
However, the estimated concentration of specific anti-Ent IgG used in our assay is in fact much
lower than the biologically relevant concentration of lipocalin 2, strongly suggesting the Entspecific IgG induced by the new vaccine displays more potent bacteriostatic effect than lipocalin
2. This statement is based on following conservative calculation. It is a well-known fact that
specific IgG directed against desired protective epitopes of a bacterial vaccine only accounts
small proportion of total serum antibodies. For example, the concentration of the IgG directed
against a highly immunogenic tetanus toxoid vaccine was 20 μg/ml in human serum (Gonzalez‐
Quintela et al., 2008; Lavinder et al., 2014). Given that total IgG in human serum was about 11
mg/ml (Gonzalez‐Quintela et al., 2008; Lavinder et al., 2014), approximately only 0.2% of
total serum IgG are the specific IgG directed against a highly immunogenic antigen (or against
all epitopes of the immunogen). Assuming this is also the case for rabbit whose serum IgG
concentration is approximately 14.5 mg/ml, the estimated concentration of specific IgG directed
against whole Ent-KLH conjugate vaccine, which includes multiple KLH epitopes and limited
Ent epitopes, is about 29 μg/ml. If simply ignoring anti-KLH IgG and assuming all KLH-Ent
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conjugate-induced antibodies target Ent only, the Ent-specific IgG in rabbit serum should be less
than 29 μg/ml or 0.19 μM. Therefore, in our Campylobacter growth promotion assay, the
estimated final concentration of anti-Ent IgG should be less than 0.07 µM, which is much lower
than the concentration of lipocalin 2 used in the same growth assay (24 μg/ml or 1.04 µM). This
evidence together with the consistently high level of antibodies in serum and mucosa due to
dynamic antibody production strongly supports that the Ent-specific antibodies induced by the
Ent conjugate vaccine would function similarly as lipocalins to limit Gram-negative infections in
animal host. In the future, the new conjugate vaccines developed in this study, such as KLH-Ent,
need to be evaluated for their protective efficacy against Gram-negative infections using
appropriate pathogen-animal model systems. Clearly, to improve protective efficacy of this new
Ent conjugate vaccine, optimization of vaccination regimen is also highly warranted to further
increase titer of the Ent-specific antibodies.
Because Ent and its related catecholate siderophores can be produced by a panel of
Gram-negative bacteria in the intestine, we should consider potential effects of such Ent
conjugate vaccine on host microbiome and physiology when performing animal studies. From
standpoint of short-term therapeutic treatment against pathogens, the concern for potential
detrimental effect of anti-Ent antibodies on microbiota should be mitigated due to wide
acceptance of broad spectrum clinical antibiotics. For this purpose, production of Ent-specific
hyperimmune egg yolk antibodies as immune therapeutics is enticing. Passive immunization
with specific egg yolk antibodies is emerging as a potential alternative to antibiotics for the
treatment and prevention of various animal and human diseases (Diraviyam et al., 2014). Laying
hens are “small factories” for cost-efficient production of large quantities of high-quality
polyclonal antibodies; the amount of egg yolk antibodies produced yearly by an immunized hen
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is over 22,500 mg with up to 10% are antigen-specific antibodies (Xu et al., 2011). We speculate
that immunization of laying hens with the Ent conjugate vaccine developed in this study can
generate high titer of Ent-specific egg yolk antibodies, which would have preventive and/or
therapeutic efficacy to control Gram-negative infections. This approach is being investigated in
our laboratory.
From standpoint of long-term prevention of animals against Gram-negative infections,
the anti-Ent antibodies induced by the Ent conjugate vaccine may reduce relative abundance of
Ent-producing bacteria. However, the potential detrimental impact resulting from anti-Ent
antibodies appears minimal. First, given the bacteriostatic nature of anti-Ent antibodies, the Entproducing bacterial population should not be dramatically reduced upon vaccination with Ent
conjugate. Second, based on recent study by Sassone-Corsi et al.(Sassone-Corsi et al., 2016),
vaccination of mice with the Ent-CTB conjugate vaccine did not significantly affect composition
of microbiota in the intestine. Following Salmonella challenge, Enterobacteriaceae population
dramatically increased in the gut of control mice while Lactobacillus spp. rather than
Enterobacteriaceae expanded significantly in the intestine of the mice immunized with Ent-CTB
conjugate vaccine (Sassone-Corsi et al., 2016). Finally, based on recent extensive microbiome
research, the Ent-based vaccine is likely even beneficial to host by limiting overpopulation of
Ent-producing bacteria. Compelling evidence showed that the increased densities of various γproteobacteria species in the gut (e.g., Enterobacteriaceae) have detrimental effects on gut health
(e.g., increased inflammation) (Bullock et al., 2004; Dicksved et al., 2008; Garrett et al., 2010;
Jostins et al., 2012; Litvak et al., 2017; Winter & Bäumler, 2014). Notably, the γ-proteobacteria
species are the major bacterial populations in the gut to produce Ent and relevant derivatives for
effective iron acquisition and survival in vivo (Fischbach et al., 2006; Miethke & Marahiel, 2007;
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Raymond et al., 2003). Therefore, the Ent conjugate vaccine may be beneficial for the host by
controlling overpopulation of γ-proteobacteria species, consequently improving gut health. This
hypothesis needs to be tested in the future.
The high-titer Ent specific antibodies developed in this study may also serve as a useful
tool for various basic and translational studies. Although the importance of catecholatesmediated iron acquisition for bacterial pathogenesis has been widely recognized, there is still a
significant knowledge gap in the in vivo status of such siderophores (Zeng & Lin, 2014).
Detection and quantitative measurement of in vivo Ent and its derivatives, particularly those in
the intestine, have been technically challenging. Limited studies using HPLC and LC/MS
techniques have shown that a significant quantity of catecholates were produced in the intestine
or air sacs (Caza et al., 2008; Pi et al., 2012). With aid of the anti-Ent antibodies, we can develop
an easier and faster immune assay to quantify the level of intestinal Ent and its derivatives used
by bacteria for effective iron acquisition. Such assays will be helpful for bacterial pathogenesis
research focused on the role of high affinity siderophore-mediated iron scavenging in bacterial
infection in host. Based on a recent report by Qi and Ban (Qi & Han, 2018), the anti-Ent
antibodies may be used to study eukaryotic host iron homeostasis in cellular processes. Finally,
the anti-Ent IgG-based immune assay may also serve as an innovative diagnosis tool to monitor
gut health. Early diagnosis of gut health has enormous impacts on timely and effective control
of many enteric diseases in animals and humans. As discussed above, the increased density of γproteobacteria species in the gut, the primary catecholates-producing population have been
observed to exert detrimental effects on gut health (Bullock et al., 2004; Dicksved et al., 2008;
Garrett et al., 2010; Jostins et al., 2012; Litvak et al., 2017; Winter & Bäumler, 2014). Therefore,
the diverse γ-proteobacteria species may serve as a promising biomarker for gut health in animal
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host. However, it is not feasible to use existing microbiological and molecular approaches to
develop a single efficient diagnosis tool for evaluation of the level of diverse γ-proteobacteria
populations in the intestine. With aid of the Ent antibodies developed in this study, we propose
that specific anti-Ent antibodies may be used to monitor intestinal level of γ-proteobacteria
species and serve as an early diagnosis tool to evaluate gut health in animals and humans.
In the context of holistic bacteria-host interaction, we should consider potential effect of
anti-Ent antibody on eukaryotic host. Recently, using Caenorhabditis elegans model and in
vitro human embryonic cell line, Qi and Ban (Qi & Han, 2018) reported that Ent is beneficial for
host iron-uptake and development through the mitochondrial ATP synthase. However, at this
stage, physiological relevance of this interesting finding in higher animal is still largely
unknown. We cannot simply translate this C. elegans discovery into higher animals, such as
mammals and other vertebrates. In particular, given the complexity of eukaryotic host and its
associated microbiome, host cell iron homeostasis and development can be influenced by
numerous factors, including various iron-binding compounds and proteins. C. elegans has only
~1,000 somatic cells and a few layers. Thus, the Ent produced by intestinal bacteria may
penetrate through the intestinal cell wall and interact with other somatic cells in C. elegans.
However, in higher animals, to date, there is no any evidence indicating that Ent can penetrate
complex intestinal wall and subsequently reach different organs and tissues. Due to sterile
nature of the environment of embryos, the mammalian embryo development and differentiation
should not be affected by the bacteria-derived Ent. Upon establishment of microbiota after birth,
as expected, Ent can be detected in specific niches in the host where Ent-producing bacteria
reside, such as inside of the intestinal tract (Pi et al., 2012) and air sac (Caza et al., 2008).
However, some studies have shown that Ent was not detected in the tissues of infected lambs
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(Der Vartanian et al., 1992) and blood/liver of infected chickens (Caza et al., 2008). Therefore,
it is still premature to speculate potential detrimental effect of ant-Ent antibody on iron
homeostasis and development of higher animals. To ensure the finding reported by Qi and Ban
(Qi & Han, 2018) is not an artificial scenario for higher animals, in the future, the effect of Ent
on eukaryotic host iron homeostasis and development must be studied in well-controlled systems
using appropriate animal model.
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Appendix I
Table 1. Major strains used in this study.

Strains

Description

Source or Reference

JL122

E. coli AN102, Ent transport mutant for Ent

(Anderson & Armstrong,

purification

2004)

JL170

C. coli strain isolated from turkey

(Xu et al., 2010)

JL241

C. jejuni NCTC 11168, human isolate

(Parkhill et al., 2000)

JL633

E. coli BL21 (DE3) recombinant strain producing

(Lin et al., 2005)

C-terminal His-tagged IroE
JL636

E. coli BL21 (DE3) recombinant strain producing

(Fischbach et al., 2005)

C-terminal His-tagged IroB
JL999

E. coli K-12 MG1655

(Garénaux et al., 2013)

JL1002

E. coli Tuner, ΔentD derivative QT2908 producing

(Garénaux et al., 2013)

His-tagged human lipocalin-2
JL243

E. coli JM109 recombinant strain producing Nterminal His-tagged CmeC
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(Zeng et al., 2010)

Figure 1. Ent conjugation with carrier proteins. (A) Schematic description of the conjugation
of Ent to a carrier protein. (B) SDS-PAGE analysis of Ent conjugation with carrier protein KLH
(left panel), BSA (middle panel), or CmeC (right panel).
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Figure 2. Optimization of conditions for conjugation of Ent to KLH and BSA. (A) Effects of
Ent concentration and temperature. Left panel is SDS-PAGE for different sample mixes
incubated at 4 °C or 37 °C for 12 hrs. Right table shows detailed recipe for all samples. Ent was
dissolved in methanol (MeOH) to final stock concentration of 50 mM. Due to high volume of
MeOH in sample 5 and 6, loading of protein samples to the gel did not work, leading to the lack
of visible proteins in lanes 5 and 6. (B) SDS-PAGE analysis of conjugation of Ent to KLH and
BSA. The same components described in Sample #2 above were scaled up for conjugation of Ent
to BSA as well as KLH; the reaction mix was incubated at 37 °C for 12 hrs. Comparable amount
of proteins from control and treatment were analyzed by SDS-PAGE. Lane 1, control containing
carrier protein only; lane 2, reaction containing both Ent and carrier protein. (This work was
performed by the collaborators Dr. Hening Lin and Dr. Bin He at Cornell University)
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Figure 3. KLH-Ent conjugate vaccine elicited significant immune response and Ent-specific
antibodies. (A) Dot blotting analysis of the reactivity of Ent antiserum to KLH, KLH-Ent, BSA,
and BSA-Ent. (B) Western blotting analysis of the reactivity of Ent rabbit antiserum to BSA,
BSA-Ent, CmeC, and CmeC-Ent. (C) Serum IgG titer to the KLH-Ent conjugate antigen in each
rabbit (designated as R1, R2, R3, and R4). Each point represents the average of duplicate
measurements. (D) Serum IgG titer to Ent molecule in each rabbit. Each point represents the
average of duplicate measurements. (E) Effect of increased coating antigen BSA-Ent (2 μg/well)
on measurement of serum anti-Ent IgG titer. The sera in four rabbits (R1-R4) collected at 14th
week postimmunization and corresponding preimmune sera were serially diluted for ELISA
analysis.
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Figure 4. In vitro synthesis of salmochelins. (A) SDS-PAGE analysis of IroB purification. Lane
1, molecular weight marker (Bio-Rad); lane 2, purified recombinant IroB. (B) HPLC analysis of
the IroB-catalyzed conversion of Ent to various salmochelins.
(MGE);

, diglucosyl-Ent (DGE);

, Ent;

, monoglucosyl-Ent

, triglucosyl-Ent (TGE). (This work was performed by the

previous postdoctoral researcher Dr. Yiming Mo)
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Figure 5. Validation of direct coating of Ent for indirect ELISA using a modified coating
method. Ent was dissolved in methanol (10 nmol/well) for direct coating on ELISA plate as
detailed in Materials and Methods. The preimmune serum and the postimmune serum (collected
at 14th week) from Rabbit R2 were 2-fold serially diluted and subjected to ELISA analysis with
the plates directly coated with Ent and the plates coated with BSA-Ent (2 μg/well). Titer was
expressed as the reciprocal of the end point dilution log2. The bars represent the means of log2
IgG titer ± standard deviations of two independent experiments with duplicate measurements
performed for each serum sample in each independent experiment.
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Figure 6. Binding specificity of anti-Ent antibodies to different Ent derivatives. Ent and its
derivatives were directly coated on ELISA plate as detailed in Materials and Methods.
Preimmune and postimmune (14th week) sera from Rabbit 2 were diluted by 4,096 folds and
served as primary antibody in indirect ELISA. Each bar represents the average of triplicate
measurements. Negative control, no antigen coated; BSA-Ent, BSA-Ent conjugate; Ent, apo Ent;
FeEnt, ferric Ent complex; Linear Ent, linear trimer of N-(2,3-dihydroxybenzoyl) serine, or
(DHBS)3; MGE, monoglucosyl-Ent; DGE, diglucosyl-Ent; TGE, triglucosyl-Ent; DHBA, 2,3Dihydroxybenzoic acid. Error bars represent standard deviation from at least two independent
experiments with duplicate measurements performed in each independent experiment.
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Figure 7. Structure of catecholate compounds.
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Figure 8. Effect of Ent-specific antibodies on Ent-mediated growth promotion in
Campylobacter. (A) SDS-PAGE analysis for purification of human lipocalin-2. 1, Marker; 2,
Protein fragments of recombinant strain before the induction of IPTG; 3, Protein fragments after
the induction with overexpression of human lipocalin-2; 4, Human lipocalin-2 eluted through NiNTA agarose column; (B) The diameters of growth zones for C. jejuni JL241 (NCTC 11168)
grown in iron-restricted MH agar supplemented with PBS, control serum (final 5.6-fold
dilution), Ent antiserum (final 5.6-fold dilution), or human lipocalin-2 (final concentration of 24
µg/ml). The bars represent the means of growth zone diameter ± standard deviations of three
independent measurements. The statistically significant differences between four groups are
indicated with asterisks (*, P<0.05).
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Figure 9. Inhibitory effect of the rabbit Ent antiserum on Ent-dependent growth promotion
in Campylobacter. (A) The diameters of growth zones for C. coli JL170 grown in iron-restricted
MH agar supplemented with PBS, control serum (final 5.6-fold dilution), Ent antiserum (final
5.6-fold dilution), or human lipocalin-2 (final concentration of 24 µg/ml). (B) The diameters of
growth zones for C. jejuni 241 (NCTC 11168) grown in iron-restricted MH agar supplemented
with PBS, control serum (final 2.9-fold dilution), Ent antiserum (final 2.9-fold dilution), or
human lipocalin-2 (final concentration of 24 µg/ml). The bars represent the means of growth
zone diameter ± standard deviations of three independent measurements. The statistically
significant differences between four groups are indicated with asterisks (*, P<0.05; **, P<0.01).
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Figure 10. Inhibitory effect of the rabbit Ent antiserum on the growth of E. coli under ironrestricted condition. The E. coli MG1655 cells were grown in RPMI medium supplemented
with rabbit control serum (4-fold dilution), anti-Ent serum (4-fold dilution), or the control serum
(4-fold dilution) plus lipocalin 2 (final concentration of 38 µg/ml). Each data point represents
the mean value obtained from duplicate wells in the microtiter plate growth assay.
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CHAPTER III: Production of Egg Yolk IgY Directed against Enterobactin
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Abstract
Passive immunization with pathogen-specific egg yolk antibodies (IgY) is emerging as a
potential alternative to antibiotics to prevent and treat microbial infections. Previous findings
have strongly supported that immune intervention by targeting enterobactin (Ent), a high-affinity
archetype of siderophore, is a promising approach to control infections caused by Gram-negative
bacterial pathogens. Recently, we have successfully developed a simple method to prepare Ent
conjugate vaccines that can induce high level of Ent-specific antibodies in rabbit. In this study,
we evaluated the capability of the Ent conjugate vaccines for production of hyperimmune egg
yolk IgY directed against Ent in laying hens. Purified Ent was conjugated to three carrier
proteins, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) and CmeC
(Campylobacter outer membrane protein). In the first trial, Barred Rock layers (n=3) were
intramuscularly immunized with 100 µg of KLH-Ent conjugate, followed by three booster
immunizations every two weeks. The KLH-Ent conjugate vaccine triggered significant immune
response in layers, leading to moderately increased titers of Ent-specific IgY in serum (up to 8
folds) and yolk (up to 2 folds). In the second trial, Rhode Island Red layers were subcutaneously
immunized with specific Ent conjugates (KLH-Ent, BSA-Ent, or CmeC-Ent; n=2 per conjugate),
followed by three booster immunizations every 3-4 weeks. ELISA analysis indicated that antiEnt IgY titers dramatically increased in serum (up to 2,048 fold) and yolk (up to 1,024 fold) of
each individual layer upon vaccination with KLH-Ent or CmeC-Ent. However, the BSA-Ent
conjugate failed to induce anti-Ent IgY. Together, this study determined optimal immunization
regimen to produce high level of innovative Ent-specific egg yolk antibodies for prevention and
control of bacterial infections.
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3.1 Introduction
Antibiotics have long been used in food animal production for growth promotion (subtherapeutic dose), disease prevention (prophylactic dose) and treatment (therapeutic dose)
(Yegani & Korver, 2010). However, antibiotic usage in food animals has been linked to the
emergence of antibiotic resistant bacteria. Antibiotic resistant bacteria as well as resistance
determinants can therefore spread from animals to humans, compromising the effectiveness of
antibiotics for treating human infections and posing a serious threat to public health (Marshall &
Levy, 2011). Due to this concern and consumer’s growing demand for livestock products from
antibiotic-free systems, the alternatives to antibiotics in food animal production are in high
demand and have become an important research area.
Immune intervention is a promising alternative approach to antibiotics to prevent and
control bacterial infections. Vaccination has been a popular and cost-effective methods to
combat bacterial infections in livestock production by enhancing disease resistance of animals
(Cheng et al., 2014). Nevertheless, there are still some issues that have significantly impeded the
development of antibacterial vaccines, especially the vaccines against enteric bacterial
pathogens. The major drawbacks of current vaccines against enteric pathogens include but are
not limited to: deficiency in triggering sufficient mucosal immune response, antigenic variation,
and susceptibility to digestion in the gastrointestinal tract via oral administration (Lycke, 2012).
Recently, administration of antibodies for passive immunity, has received increased attention due
to the direct and rapid protection against infectious pathogens or toxins (Hedegaard & Heegaard,
2016). Because of transient nature of the protection provided by passively transferred antibodies,
repeated or continuous antibody administration is necessary, and large amounts of antigenspecific antibodies are required, especially when used orally. To this end, hen’s egg can be an
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excellent source of large quantities of antibodies (IgY) used for passive immunization
applications (Kovacs-Nolan & Mine, 2012).
IgY in chicken serum and egg yolk is equivalent to IgG in mammals. However, compared
to the IgG in mammalian counterpart, production of hyperimmune egg yolk IgY from laying
hens is much more efficient. It was shown that an immunized hen can produce approximately
1,500 mg of egg yolk IgY in one month, 2-10% of which is antigen-specific. However, an
immunized rabbit produces 18 times less IgG from serum in the same time period (Gadde et al.,
2015). Additionally, compared to blood collection in mammals, IgY production is less invasive
and more sustainable, which only requires the daily collection of eggs and makes the large-scale
production of IgY technically feasible (Karlsson et al., 2004). Moreover, IgY is fairly stable
during storage and processing. IgY is also relatively stable between pH 4 and pH 11, especially
with the addition of stabilizers (Kovacs-Nolan & Mine, 2012). Therefore, passive immunization
with specific egg yolk antibodies is emerging as a potential alternative to antibiotics for the
treatment and prevention of various bacterial infections in human and animal.
Enterobactin (Ent), a catecholate siderophore produced by most members of
Enterobacteriaceae and displaying the highest affinity to ferric iron among all natural
siderophores (Raymond et al., 2003), is a promising target of immune intervention as
demonstrated in Chapter 2. In particular, the novel KLH-Ent conjugate vaccine could trigger
high titer of Ent-specific IgG in rabbits (up to 4,096-fold increase). The anti-Ent IgG could crossreact with various Ent derivatives (such as linearized Ent and different salmochelins) and inhibit
Ent-mediated growth promotion in both Escherichia coli and Campylobacter under ironrestricted conditions (Chapter 2). These data together with the promising features of egg yolk
IgY as passive immune agent prompted us to hypothesize that Ent conjugate vaccines can induce

85

high level of anti-Ent egg yolk IgY in layers and facilitated us to produce sufficient Ent-specific
antibodies for passive immune protection against Gram-negative bacterial infections.
In this study, in order to determine appropriate conditions to produce large amount of
Ent-specific egg yolk IgY, laying hens were immunized with different Ent conjugate vaccines
via different vaccination routes. Subcutaneous immunization of laying hens with KLH-Ent
conjugate was found to induce the highest level of anti-Ent IgY in both serum and egg yolk. The
high level of Ent-specific IgY in egg yolk was demonstrated to be maintained after the
lyophilization process. This study lays a solid foundation for evaluating the passive immune
protection of Ent-specific egg yolk IgY against different Gram-negative infections in the future.

3.2 Materials and methods
3.2.1 Ent purification and conjugation with carrier proteins
Ent was purified from E. coli AN102, an Ent transport mutant, as detailed in Chapter 2.
Carrier proteins BSA and KLH were purchased from Thermo Fisher Scientific (Waltham, MA).
Recombinant CmeC was purified as described in a previous study (Zeng et al., 2010). Scale-up
conjugation of Ent with BSA, KLH, or CmeC was performed using the same protocol as
described in Chapter 2. Successful conjugation of Ent to KLH (KLH-Ent), BSA (BSA-Ent), or
CmeC (CmeC-Ent) was confirmed by SDS-PAGE and further validated by immunoblotting as
detailed in Chapter 2.
3.2.2 Immunization of layers with Ent conjugate vaccines
Two independent immunization trials were performed to explore the optimal
immunization regimen to produce high levels of Ent-specific egg yolk IgY. The first trial was
performed at Johnson Animal Research and Teaching Unit (JARTU) at the University of
Tennessee using KLH-Ent conjugate, as outlined in Table 2. Six Barred Rock pullets were
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purchased from McMurray Hatchery (Iowa) and raised by the age of 26 weeks when pullets
started to lay eggs routinely. One group of layers (n=3) received primary immunization via
intramuscular injection (in breast) with 100 µg of KLH-Ent conjugate emulsified with Freund's
complete adjuvant, followed by three booster immunizations (100 µg of KLH-Ent conjugate
emulsified with Freund's incomplete adjuvant) every 2 weeks. The other group of layers (n=3)
that did not receive any vaccinations were served as non-immunized control. Blood samples of
each layer were collected from the wing vein at different time points to monitor the systemic
immune responses. All eggs along the whole trial were also collected and stored at -4 °C. Layers
were euthanized at week 11 postimmunization. The second trial was performed by Pacific
Immunology Corp. (Ramona, CA), as outlined in Table 3. Compared to the first trial, this trial
used different conjugate vaccines (BSA-Ent, KLH-Ent, and CmeC-Ent) and immunization route
(subcutaneous route). Briefly, six Rhode Island Red layers (two hens for each vaccine) received
primary immunization via subcutaneous injection (under the neck skin near the shoulders) with
100 µg of Ent conjugates emulsified with Freund's complete adjuvant, followed by three booster
immunizations (100 µg of Ent conjugate emulsified with Freund's incomplete adjuvant) every 34 weeks. Blood samples of each layers were collected from the wing vein at different time points
to monitor the systemic immune responses. All eggs along the whole trial were also collected
and stored at -4 °C for future analysis and processing.
3.2.3 Enzyme-linked immunosorbent assay (ELISA)
The immune response in serum and egg yolk was measured by indirect ELISA using the
same protocol detailed in Chapter 2 with minor modifications. For egg yolk, each sample was
diluted with sterile PBS (1/1, v/v) prior to the assay. The rest of ELISA procedure for egg yolk
was the same as that for serum. To examine the general antibody responses in serum and egg
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yolk samples immunized with KLH-Ent, BSA-Ent, or CmeC-Ent, 100 μl of KLH-Ent, BSA-Ent,
or CmeC-Ent was coated on microtiter plates (30 ng/well). To examine the level of Ent-specific
antibody in serum and egg yolk samples, 100 μl of BSA-Ent was coated on microtiter plates (2
μg/well) for detection of Ent-specific IgY in the samples from layers immunized with KLH-Ent
or CmeC-Ent, while 100 μl of KLH-Ent was coated (2 μg/well) for detection of Ent-specific IgY
in the samples from layers immunized with BSA-Ent. In addition, to determine Ent-specific IgY
in the serum for serum and egg yolk samples from layers immunized with BSA-Ent, 1% (w/v)
fish gelatin (Sigma-Aldrich, MO) was used in blocking buffer to minimize the background due
to non-specific binding.
3.2.4 Lyophilization of egg yolk
The pooled egg yolk was lyophilized using the freeze dryer (VirTis AdVantage Plus EL85 Benchtop Lyophilizer, SP Scientific Inc., NY) for evaluating in vivo efficacy of Ent-specific
IgY in the future. The egg yolks from control group or the group subcutaneously immunized
with KLH-Ent conjugate were pooled and diluted with sterile PBS (1/1, v/v). Then the mixture
was stirred evenly using a sterilized egg whisk and transferred into metal trays with approximate
500 ml per tray. The trays were subsequently wrapped by aluminum foil with several small pores
for evaporation. The trays containing egg yolks were put in -80 °C freezer overnight for
complete solidification of egg yolk mixture prior to lyophilization. Under manual mode of the
lyophilizer machine, the egg yolk was processed for about 72 hours. Lastly, the freeze-dried egg
yolk was pulverized into powder using a mortar and stored at -20 °C until use. To determine Entspecific IgY level in lyophilized egg yolk, 0.1 g of immunized and non-immunized egg yolk
powders were dissolved in 1 ml of sterile PBS. The solutions were subjected to indirect ELISA
as described above.
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3.3 Results
3.3.1 Conjugation of Ent with carrier proteins
A total of approximately 10 mg of KLH-Ent, 5 mg of BSA-Ent, and 5 mg of CmeC-Ent
conjugates were prepared using the conjugation protocol described in Chapter 2. Successful
conjugation of Ent with KLH, BSA, or CmeC was further validated using SDS-PAGE and
Immunoblotting, leading to the same results as shown in Figure 1B and Figure 3B. These
conjugates were subsequently used for immunization trials and ELISA assay in this study.
3.3.2 Immune responses induced by intramuscular vaccination with KLH-Ent conjugate
Intramuscular vaccination of Barred Rock layers with KLH-Ent conjugate vaccine
triggered significant immune responses in serum and egg yolk, while there was no immune
response in control layers. With regard to the IgY response against the whole KLH-Ent
conjugate, in serum (Figure 11A), the ELISA titers of anti-KLH-Ent IgY were elevated by 1-3
log2 units (or 2- to 8-fold increase) upon primary immunization, and were further enhanced and
maintained by booster immunizations with an increase of up to 4 log2 units; in egg yolk (Figure
11B), the IgY titers against KLH-Ent conjugate were elicited by 2-4 log2 units (or 4- to 16-fold
increase) upon primary immunization, and were dramatically boosted and maintained by booster
immunizations with an increase of up to 7 log2 units (or 128 folds). For the individual haying hen
(Figure 12A and B), the IgY titers in serum or egg yolk showed the similar trend as in Figure 11
and there was minor variation within each group. With regard to the IgY response directed
against Ent, serum anti-Ent IgY did not increase upon primary immunization but was
subsequently induced and maintained due to booster immunizations with an increase of up to 3
log2 units (or 8 folds) (Figure 13A). In egg yolk, anti-Ent IgY level did not increase upon
immunization of layers with KLH-Ent. The anti-Ent IgY level did not differ between vaccination
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and control groups either (Figure 13B). For the individual laying hen (Figure 14A and B), there
were generally similar levels of Ent-specific IgY in serum or egg yolk of six layers, which also
confirmed the fairly low level of Ent-specific IgY.
3.3.3 Immune responses induced by subcutaneous vaccination with KLH-Ent conjugate
In contrast to the very strong anti-Ent IgG response (up to 12 log2 units or a 4,096-fold
increase) in rabbit sera induced by subcutaneous vaccination of KLH-Ent conjugate (Figure 3E
in Chapter 2), only weak anti-Ent IgY response was induced in the serum and yolk of layers by
intramuscular vaccination of layers with the same KLH-Ent conjugate. So we speculated that the
choice of immunization route may play an important role in inducing desired level of specific
immune response to Ent. To test this, we subsequently immunized two Rhode Island Red layers
with KLH-Ent conjugate via subcutaneous route.
Subcutaneous vaccination of Rhode Island Red layers with the KLH-Ent conjugate
triggered strong immune response in serum and egg yolk. With respect to the IgY titer against
the whole KLH-Ent conjugate, the titers of anti-KLH-Ent IgY in serum (Figure 15A and B) were
drastically elicited by 7-8 log2 units (or 128- to 256-fold increase) by 9 weeks postimmunization,
and were slightly dropped afterwards. Similarly, the IgY titers against KLH-Ent conjugate in egg
yolk (Figure 15C and D) were dramatically increased about 128 folds by 9 weeks
postimmunization and maintained at comparably high level through the remaining period. With
respect to the Ent-specific IgY titer, the titers of anti-Ent IgY in serum (Figure 16A and B) were
drastically induced by 7-8 log2 units (or 128- to 256-fold increase) upon primary immunization
and two booster immunizations, and were maintained through the rest of period. The titers of
anti-Ent IgY in yolk (Figure 16C and D), were significantly elevated by 6-8 log2 units (or 64- to
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256-fold increase) upon primary immunization and two booster immunizations, and were
generally maintained through the rest of period.
3.3.4 Immune responses induced by subcutaneous vaccination with BSA-Ent or CmeC-Ent
conjugate
Comparing the quite different levels of Ent-specific IgY induced by intramuscular or
subcutaneous vaccination with the same KLH-Ent conjugate vaccine, we concluded that
immunization route could be an important factor to affect the immune response of Ent conjugate
vaccine. Then we further speculated that the carrier protein conjugated to Ent may be another
factor affecting the immune response to Ent. To test this, we immunized the Rhode Island Red
layers with BSA-Ent and CmeC-Ent conjugate vaccines (two layers for each vaccine) using the
similar immunization regimen as the above.
Subcutaneous vaccination of Rhode Island Red layers with the BSA-Ent conjugate
triggered significant immune response in serum and egg yolk. As to the IgY titer against the
whole BSA-Ent conjugate, the titers of anti-BSA-Ent IgY in serum (Figure 17A and B) were
elicited by 3-8 log2 units (or 8- to 256-fold increase) after primary immunization and two booster
immunizations, and were generally maintained throughout the rest of period. The IgY titers
against BSA-Ent conjugate in egg yolk (Figure 17C and D) were dramatically triggered by 6-8
log2 units (or 64- to 256-fold increase) after primary immunization and two booster
immunizations, and were maintained through the remaining period, except for a drop of 3 log2
units in one layer at week 12 postimmunization. However, as to the Ent-specific IgY titer, there
was generally minor increase of anti-Ent IgY in serum (Figure 18A and B) and egg yolk (Figure
18C and D) along the whole immunization process, despite an increase of 4 log2 units (or 16-fold
increase) in one egg yolk sample at week 7 postimmunization.
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Subcutaneous vaccination of Rhode Island Red layers with the CmeC-Ent conjugate
elicited strong immune response in serum and egg yolk. As for the IgY titer against the whole
CmeC-Ent conjugate, the titers of anti-CmeC-Ent IgY in serum (Figure 19A and B) were
drastically elicited by 5-8 log2 units (or 32- to 256-fold increase) after primary immunization and
two booster immunizations, and were maintained throughout the remaining process. Similarly,
the IgY titers against CmeC-Ent conjugate in egg yolk (Figure 19C and D) were significantly
triggered by 5 log2 units (or 32-fold increase) after primary immunization and two booster
immunizations, and were slightly lowered through the remaining process regardless of the third
booster immunization at week 10 postimmunization. As for the Ent-specific IgY titer, in general,
the titers of anti-Ent IgY were dramatically induced (up to 10 log2 units or 1,024-fold increase)
in both serum (Figure 20A and B) and egg yolk (Figure 20C and D) upon primary immunization
and two booster immunizations, but there were significant variations in Ent-specific IgY level
between two layers, which primarily resulted from the comparatively much lower level of IgY
titer in both serum and egg yolk of layer 2, except for a drastic increase of 10 log2 units in its egg
yolk at week 7 postimmunization.
3.3.5 The titer of Ent-specific IgY in lyophilized egg yolk powder
Since the Rhode Island Red layers immunized with KLH-Ent conjugate vaccine
displayed the highest and stable IgY response against Ent throughout the entire period (Figure
16), their immunized egg yolk could be used for future in vivo passive immunization assays.
Meanwhile, egg yolk from non-immunized Rhode Island Red layers was served as control. The
pooled egg yolks from each group were lyophilized into powder. To confirm the activity of Entspecific IgY was not affected by lyophilization process, KLH-Ent-immunized and control egg
yolk powder was dissolved in PBS to the concentration of 0.1 g/ml, and was subsequently
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subjected to indirect ELISA. The IgY titer in KLH-Ent-immunized egg yolk powder was much
higher than control by 7 log2 units (Figure 21). This titer difference was generally consistent with
the differences of average IgY titers in egg yolk between preimmune and postimmune (Figure
16C), demonstrating the lyophilization process did not affect the activity of Ent-specific IgY in
egg yolk powder.

3.4 Discussion
Siderophore-mediated iron acquisition has been a historically important research area in
bacterial pathogenesis and has been targeted for developing various pathogen control strategies.
However, those strategies have had only partial success primarily due to complexity of
siderophore synthesis and redundancy of siderophore utilization systems in various Gramnegative pathogens. In Chapter 2 study using rabbit as a model, a novel Ent conjugate vaccine
was successfully developed for inducing high level of Ent-specific antibodies, which displayed
significant inhibitory effect on Ent-dependent growth of Campylobacter and E. coli. The findings
from Chapter 2 study laid a solid foundation for producing hyperimmune Ent-specific egg yolk
IgY as explored in this study.
The promising applications of egg yolk IgY as passive immune agent against bacterial
pathogens have been well demonstrated. For example, oral administration of egg yolk IgY
against Salmonella enteritidis was found to reduce fecal shedding and cecal colonization of
Salmonella and even the rate of Salmonella-contaminated eggs in experimentally infected
chickens (Gürtler et al., 2004). Feeding broilers IgY-rich yolks from hens immunized with C.
jejuni dramatically reduced both C. jejuni colonization in the ceca after challenge with the
homologous strain and transmission to non-inoculated contact birds (Hermans et al., 2014). Egg
yolk IgY against Helicobacter pylori could reduce bacterial adhesion, growth, and urease activity
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in vitro and decrease H. pylori-induced gastric mucosal injury and inflammation in Mongolian
gerbil (Shin et al., 2002). Together, such encouraging evidence strongly entices us to utilize Ent
conjugate vaccines to develop sufficient level of Ent-specific egg yolk IgY for passive immune
protection against Gram-negative pathogens.
In this study, we performed immunization trials using different Ent conjugate vaccines
and vaccination routes in order to optimize the production of sufficient level of Ent-specific IgY
in egg yolk. For Rhode Island Red layers subcutaneously immunized with KLH-Ent, BSA-Ent,
or CmeC-Ent conjugate, immunization with KLH-Ent conjugate induced the highest level of
anti-Ent IgY in both serum and egg yolk. Immunization with CmeC-Ent conjugate also triggered
high level of anti-Ent IgY in serum and egg yolk but with significant variation between two
layers within the group. Immunization with BSA-Ent conjugate only elicited minor immune
response directed against Ent, despite of strong IgY response against the whole BSA-Ent
conjugate in serum and egg yolk. Such evidence indicates that different carrier proteins coupled
to Ent can affect the level of Ent-specific IgY in serum and egg yolk and KLH is currently the
most effective carrier protein that can help to induce sufficient levels of Ent-specific egg yolk
IgY in layers. This may be due to multiple reasons. First, KLH is isolated from keyhole limpets
that are evolutionarily distant from vertebrates, so it is very "foreign" for laying hens to
effectively recognize the antigen and produce antibodies. It also has very large size (400 kDa)
and complex structure, leading to high immunogenicity. Third, each KLH molecule contains
hundreds of surface lysine groups covalently coupled to Ent, therefore each KLH can present
more Ent haptens to host immune system. Last, KLH is also a naturally occurring
immunoadjuvant that can prolong the T-cell dependent antibody response (Kantele et al., 2011;
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Swaminathan et al., 2014). These features make KLH a highly immunogenic and effective carrier
protein for inducing higher level of Ent-specific IgY in layers than BSA and CmeC.
Moreover, comparing the layers either subcutaneously or intramuscularly immunized
with the same KLH-Ent conjugate, we found subcutaneous immunization dramatically elevated
Ent-specific IgY in serum and egg yolk while intramuscular immunization triggered only
moderate levels of Ent-specific IgY, in spite of significant levels of IgY against the whole
conjugate, in serum and egg yolk. This implies that subcutaneous immunization can be a more
efficient route than intramuscular immunization in eliciting high level of Ent-specific IgY in
layers. We reason this phenomenon is probably due to that subcutaneous tissue is characterized
as poor vascularity and a tendency to retain injected material (Chowdhury & Meyer, 2002),
therefore subcutaneously administrated KLH-Ent conjugate may be more slowly exposed to host
immune system and prolong the stimulation of Ent-specific immune response in laying hen.
Notably, for ELISA titers of preimmune or non-immune samples, comparatively high
background titers (i.e., ≥12 log2 units) were observed in serum or egg yolk samples from Trial 1
(Figure 11-14). We speculate that the laying hens may be colonized by Ent-producing
Enterobacteriaceae prior to the beginning of immunization trial. To establish intestinal
colonization before either a commensal or pathogenic interaction with the host, Ent-producing
Enterobacteriaceae, like Salmonella or E.coli, will counteract iron-limited niches by secreting
Ent to compete for iron from host or normal microbiota (Nagy et al., 2013; Pi et al., 2012).
Therefore, the preexistence of Ent in chicken’s intestine, as an external compound, will elicit
certain level of Ent-specific IgY, leading to increased background titers in preimmune or nonimmune serum or egg yolk. Despite of the high background titer, since there was no significant
elevation (i.e., ≥2 log2 units of increase) of Ent-specific IgY titer in postimmune serum or egg
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yolk (Figure 13), we can still confirm there was only moderate effect of intramuscular
immunization of KLH-Ent conjugate in inducing Ent-specific IgY in laying hens.
Since we have utilized Ent conjugate vaccine to successfully produce high level of Entspecific IgY in serum and egg yolk of layers, it may pave the way for broad applications of large
scale of Ent-specific egg yolk IgY against Gram-negative pathogens. In a recent work, intranasal
administration of another Ent conjugate vaccine (CTB-Ent) elicited Ent-specific IgA in the
intestinal mucosa of mice and reduced the colonization of Salmonella (Sassone-Corsi et al.,
2016). Nevertheless, there was quite limited level of induced Ent-specific IgA, regardless of
widely demonstrated adjuvant feature of CTB to induce strong mucosal immune response. From
this perspective, oral intake of egg yolk containing high level of Ent-specific IgY can be
advantageous since continuous administration of such hyperimmune egg yolk may provide
constantly high level of Ent-specific antibodies, which therefore may better inhibit the enteric
colonization of Gram-negative pathogens. Additionally, for immunodeficient humans or animals
(e.g., neonates), they are more susceptible to enteritis or diarrhea caused by enteric Gramnegative pathogens, and normal vaccinations are insufficient to induce active immune protection
against the corresponding pathogens. To this end, continuous administration of hyperimmune
egg yolk containing high level of Ent specific IgY can present steady passive immune protection
again the pathogens.
Since high titer of Ent-specific IgY in hen’s serum can be transferred into the laid eggs,
in poultry industry, hens can be immunized with Ent conjugate vaccines, conferring sufficient
maternal Ent-specific IgY for newly hatched chicks against Gram-negative pathogens. This
maternal immunization strategy overcomes some significant challenges in poultry immunization.
Namely, underdeveloped immune function and certain suppressive maternal antibodies in chicks
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within the age of 2 weeks result in ineffective vaccination; broilers reach slaughter weight by the
age of 5-6 weeks, inadequate time period for induction of immunity (Hodgins et al., 2015).
To conclude, this study, through different immunization trials, has identified the optimal
immunization regimen to produce high level and large quantity of Ent-specific egg yolk IgY, i.e.,
subcutaneous immunization of layers with KLH-Ent conjugate vaccine. At this stage, we have
lyophilized egg yolk containing high level of Ent-specific IgY into powder, and confirmed the
activity of Ent-specific IgY was maintained after the process. In the future study, we will utilize
the hyperimmune egg yolk power as feed additive, feed model animals with such additive, and
test the passive immune protection of anti-Ent egg yolk against enteric bacterial pathogens (e.g.,
Campylobacter, E. coli, or Salmonella). These studies will significantly contribute to the
development of hyperimmune egg yolk IgY as an effective alternative to antibiotics for
prevention and control of various bacterial pathogens.
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Appendix II
Table 2. Immunization of Barred Rock layers with KLH-Ent conjugate (Trial 1).

Group

No. of
Chickens

Immunogen

Immunization
Route

1

3

None

N/A

2

3

KLH-Ent
(100 µg/bird)

Intramuscular

Primary
Immunization
(week)a
26

a. Freund’s complete adjuvant was used (1/1, v/v).
b. Freund’s incomplete adjuvant was used (1/1, v/v).
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Booster
Immunization
(week)b

Sample
Collections (week)

28, 30, 32

Blood: 26, 28, 30,
32, 37
Eggs: along the
whole trial

Table 3. Immunization of Rhode Island Red layers with KLH-Ent, BSA-Ent, or CmeC-Ent
conjugate (Trial 2).

Immunogen
(100 µg/bird)

No. of
Chickens

Immunization
route

BSA-Ent

2

Subcutaneous

KLH-Ent

2

Subcutaneous

CmeC-Ent

2

Subcutaneous

Primary
Immunization
(week)a

Booster
Immunization
(week)b

Sample Collections
(week)
Blood: 33, 35, 38

26

a. Freund’s complete adjuvant was used (1/1, v/v).
b. Freund’s incomplete adjuvant was used (1/1, v/v).
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29, 32, 36

Eggs: along the
whole trial

Figure 11. General immune response (anti-KLH-Ent IgY) in the Barred Rock layers in
vaccination and control groups. (A) Serum IgY titers against the KLH-Ent conjugate. (B) Egg
yolk IgY titers against the KLH-Ent conjugate. Each point represents the average IgY titer of
three layers in vaccination or control group.
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Figure 12. General immune response (anti-KLH-Ent IgY) in the individual Barred Rock
layer in control group (C1-C3) and vaccination group (V1-V3). (A) Serum IgY titers against
the KLH-Ent conjugate in each laying hen. (B) Egg yolk IgY titers against the KLH-Ent
conjugate in each laying hen. Each point represents mean IgY titer from duplicate measurement.
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Figure 13. Ent-specific IgY immune response in the Barred Rock layers in vaccination and
control groups. (A) Serum IgY titers directed against Ent. (B) Egg yolk IgY titers directed
against Ent. Each point represents the average IgY titer of three layers in vaccination or control
group.
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Figure 14. Ent-specific IgY immune response in the individual Barred Rock layer in
control group (C1-C3) and vaccination group (V1-V3). (A) Serum IgY titers directed against
Ent in each laying hen. (B) Egg yolk IgY titers directed against Ent in each laying hen. Each
point represents mean IgY titer from duplicate measurement.
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Figure 15. General immune response (anti-KLH-Ent IgY) in the two Rhode Island Red
layers (K1, K2) immunized with KLH-Ent conjugate. (A) The average serum IgY titers
against the KLH-Ent conjugate in two layers. (B) The individual serum IgY titers against the
KLH-Ent conjugate in two layers. (C) The average egg yolk IgY titers against the KLH-Ent
conjugate in two layers. (D) The individual egg yolk IgY titers against the KLH-Ent conjugate in
two layers. In (A) and (C), each point represents the average IgY titer of two layers. In (B) and
(D), each point represents mean IgY titer from duplicate measurement.
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Figure 16. Ent-specific immune response (anti-Ent IgY) in the two Rhode Island Red layers
(K1, K2) immunized with KLH-Ent conjugate. (A) The average serum IgY titers directed
against Ent in two layers. (B) The individual serum IgY titers directed against Ent in two layers.
(C) The average egg yolk IgY titers directed against Ent in two layers. (D) The individual egg
yolk IgY titers directed against Ent in two layers. In (A) and (C), each point represents the
average IgY titer of two layers. In (B) and (D), each point represents mean IgY titer from
duplicate measurement.
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Figure 17. General immune response (anti-BSA-Ent IgY) in the two Rhode Island Red
layers (B1, B2) immunized with BSA-Ent conjugate. (A) The average serum IgY titers against
the BSA-Ent conjugate in two layers. (B) The individual serum IgY titers against the BSA-Ent
conjugate in two layers. (C) The average egg yolk IgY titers against the BSA-Ent conjugate in
two layers. (D) The individual egg yolk IgY titers against the BSA-Ent conjugate in two layers.
In (A) and (C), each point represents the average IgY titer of two layers. In (B) and (D), each
point represents mean IgY titer from duplicate measurement.
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Figure 18. Ent-specific immune response (anti-Ent IgY) in the two Rhode Island Red layers
(B1, B2) immunized with BSA-Ent conjugate. (A) The average serum IgY titers directed
against Ent in two layers. (B) The individual serum IgY titers directed against Ent in two layers.
(C) The average egg yolk IgY titers directed against Ent in two layers. (D) The individual egg
yolk IgY titers directed against Ent in two layers. In (A) and (C), each point represents the
average IgY titer of two layers. In (B) and (D), each point represents mean IgY titer from
duplicate measurement.
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Figure 19. General immune response (anti-CmeC-Ent IgY) in the two Rhode Island Red
layers (C1, C2) immunized with CmeC-Ent conjugate. (A) The average serum IgY titers
against the CmeC-Ent conjugate in two layers. (B) The individual serum IgY titers against the
CmeC-Ent conjugate in two layers. (C) The average egg yolk IgY titers against the CmeC-Ent
conjugate in two layers. (D) The individual egg yolk IgY titers against the CmeC-Ent conjugate
in two layers. In (A) and (C), each point represents the average IgY titer of two layers. In (B) and
(D), each point represents mean IgY titer from duplicate measurement.
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Figure 20. Ent-specific immune response (anti-Ent IgY) in the two Rhode Island Red layers
(C1, C2) immunized with CmeC-Ent conjugate. (A) The average serum IgY titers directed
against Ent in two layers. (B) The individual serum IgY titers directed against Ent in two layers.
(C) The average egg yolk IgY titers directed against Ent in two layers. (D) The individual egg
yolk IgY titers directed against Ent in two layers. In (A) and (C), each point represents the
average IgY titer of two layers. In (B) and (D), each point represents mean IgY titer from
duplicate measurement.
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Figure 21. The titer of Ent-specific IgY in the lyophilized egg yolk powder. Immunized egg
yolk powder was from Rhode Island Red layers vaccinated with KLH-Ent conjugate while
control egg yolk powder was from non-vaccinated Rhode Island Red layers. Each bar represents
the average of duplicate measurement of ELISA.
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CHAPTER IV: Conclusion
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Ent-mediated high affinity iron acquisition is critical for Gram-negative bacteria to
survive in the host. Given the bacteriostatic effect of lipocalin resulting from its potent Entbinding ability, immune intervention directly targeting Ent is promising for iron-dependent
pathogen control. Recently, an Ent conjugate vaccine was reported but it still has several
significant weaknesses. In the first study, using a simple biochemical method, we successfully
conjugated purified Ent to different carriers including KLH, BSA, and CmeC, a vaccine
candidate for Campylobacter control. Subcutaneous immunization of rabbits with the KLH-Ent
conjugate triggered strong systemic IgG immune response with up to 16,384 fold increase in IgG
titer directed against whole conjugate and up to 4,096 fold increase in the level of specific antiEnt IgG. To evaluate the binding ability of Ent-specific IgG to the Ent derivatives present in
vivo, various Ent derivatives were chemically synthesized and a unique ELISA method was
developed. The Ent-specific IgG also displayed exceptional reactivity to ferric Ent, linear trimer
of Ent, and different salmochelins. Growth assays further demonstrated the Ent-specific
antibodies significantly inhibited Ent-dependent growth of Campylobacter spp. and E. coli.
In the second study, using different vaccination regimens, we immunized laying hens
with different Ent conjugate vaccines to produce Ent-specific egg yolk IgY. In the first trial,
Barred Rock layers (n=3) were intramuscularly immunized with the KLH-Ent conjugate vaccine,
which triggered significant immune response in layers, leading to moderately increased titers of
Ent-specific IgY in serum (up to 8 folds) and yolk (up to 2 folds). In the second trial, Rhode
Island Red layers were subcutaneously immunized with specific Ent conjugates (KLH-Ent, BSAEnt, or CmeC-Ent; n=2 per conjugate). ELISA analysis indicated that anti-Ent IgY titers
dramatically increased in serum (up to 2,048 fold) and yolk (up to 1,024 fold) of each individual
layer upon vaccination with KLH-Ent or CmeC-Ent. However, the BSA-Ent conjugate failed to
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induce anti-Ent IgY. The hyperimmune egg yolks were pooled and lyophilized for future
evaluation of in vivo passive immune protection.
Collectively, these studies have demonstrated the feasibility of developing Ent-specific
antibodies as innovative and effective immune interventions and especially laid solid foundation
for producing hyperimmune Ent-specific egg yolk IgY as a passive immune agent against Gramnegative bacterial pathogens.
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